

L Jeffrey Medeiros

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/754983/publications.pdf](https://exaly.com/author-pdf/754983/publications.pdf)

Version: 2024-02-01

988
papers

43,573
citations

2298

95
h-index

6136

153
g-index

1059
all docs

1059
docs citations

1059
times ranked

28935
citing authors

#	ARTICLE	IF	CITATIONS
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> , 2022, 36, 1720-1748.	7.3	1,398
2	The Heidelberg classification of renal cell tumours. <i>Journal of Pathology</i> , 1997, 183, 131-133.	4.4	1,176
3	Pathologic Features of Prognostic Significance in Adrenocortical Carcinoma. <i>American Journal of Surgical Pathology</i> , 1989, 13, 202-206.	3.8	746
4	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	1.4	614
5	T-Cell Lymphoma Involving Subcutaneous Tissue. <i>American Journal of Surgical Pathology</i> , 1991, 15, 17-27.	3.8	442
6	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	1.4	396
7	Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 160-168.	5.7	359
8	Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 114-120.	5.7	341
9	Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 607-622.	2.9	317
10	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 3986-3996.	1.4	313
11	Application Challenges in Fiber and Textile Electronics. <i>Advanced Materials</i> , 2020, 32, e1901971.	23.6	303
12	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. <i>Blood</i> , 2008, 111, 5530-5536.	1.4	296
13	U.S. Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Plastic and Reconstructive Surgery</i> , 2017, 139, 1042-1050.	1.6	281
14	Whole-genome sequencing identifies recurrent somatic <i>NOTCH2</i> mutations in splenic marginal zone lymphoma. <i>Journal of Experimental Medicine</i> , 2012, 209, 1553-1565.	8.6	278
15	Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. <i>Blood</i> , 2006, 107, 4207-4213.	1.4	250
16	Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. <i>Modern Pathology</i> , 2016, 29, 753-763.	5.6	249
17	Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. <i>Cancer</i> , 2003, 97, 586-591.	4.0	236
18	Benefit of Consolidative Radiation Therapy in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 4170-4176.	5.7	225

#	ARTICLE	IF	CITATIONS
19	B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. <i>Modern Pathology</i> , 2012, 25, 145-156.	5.6	225
20	Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. <i>Cancer</i> , 1988, 61, 1639-1651.	4.0	224
21	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	1.4	209
22	Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 904-910.	5.7	207
23	Precursor B-cell Lymphoblastic Lymphoma. <i>American Journal of Surgical Pathology</i> , 2000, 24, 1480-1490.	3.8	205
24	Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 220-226.	2.9	202
25	Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosaiâ€Dorfman disease. <i>Modern Pathology</i> , 2017, 30, 1367-1377.	5.6	202
26	Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. <i>Blood</i> , 2009, 113, 4144-4152.	1.4	197
27	Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. <i>Modern Pathology</i> , 2006, 19, 25-33.	5.6	196
28	Landscape of DNA Virus Associations across Human Malignant Cancers: Analysis of 3,775 Cases Using RNA-Seq. <i>Journal of Virology</i> , 2013, 87, 8916-8926.	3.4	194
29	Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 48-56.	10.6	194
30	TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. <i>Blood</i> , 2003, 101, 5007-5009.	1.4	184
31	Malignant Lymphomas Involving the Ovary. <i>American Journal of Surgical Pathology</i> , 1993, 17, 154-170.	3.8	173
32	Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2011, 12, 1222-1228.	10.6	171
33	Non-Hodgkin's Lymphomas Involving the Uterus: A Clinicopathologic Analysis of 26 Cases. <i>Modern Pathology</i> , 2000, 13, 19-28.	5.6	168
34	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. <i>Haematologica</i> , 2014, 99, 465-473.	3.4	167
35	A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. <i>Cancer</i> , 2003, 98, 310-314.	4.0	160
36	Lymphomas Involving the Breast. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1299-1309.	3.8	160

#	ARTICLE	IF	CITATIONS
37	Anaplastic Large Cell Lymphoma Associated With Breast Implants. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1000-1008.	3.8	156
38	Hypopigmented Mycosis Fungoides. <i>American Journal of Surgical Pathology</i> , 2002, 26, 450-457.	3.8	155
39	Survivin Expression Predicts Poorer Prognosis in Anaplastic Large-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 1682-1688.	5.7	155
40	Extranodal lymphomas of the head and neck. <i>Annals of Diagnostic Pathology</i> , 2005, 9, 340-350.	1.3	155
41	Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. <i>Blood</i> , 2016, 127, 2742-2750.	1.4	155
42	Acute Myeloid Leukemia With <i>IDH1</i> or <i>IDH2</i> Mutation. <i>American Journal of Clinical Pathology</i> , 2011, 135, 35-45.	0.7	149
43	Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma. <i>Oncogene</i> , 2004, 23, 5426-5434.	5.8	148
44	Genetic alterations and their clinical implications in DLBCL. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 634-652.	27.1	146
45	Localization of Epstein-Barr Viral Genomes in Angiocentric Immunoproliferative Lesions. <i>American Journal of Surgical Pathology</i> , 1992, 16, 439-447.	3.8	145
46	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , 2013, 98, 255-263.	3.4	143
47	Ovarian Non-Hodgkin's Lymphoma: A Clinicopathologic Study of Eight Primary Cases. <i>Modern Pathology</i> , 2001, 14, 1093-1099.	5.6	137
48	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 2260-2267.	5.7	137
49	Hepatosplenic and Other $\hat{\beta}^1$ T-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2007, 127, 869-880.	0.7	136
50	Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 1-14.	2.5	136
51	Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. <i>Blood</i> , 2002, 100, 3369-3373.	1.4	133
52	Adult Renal Epithelial Neoplasms. <i>American Journal of Clinical Pathology</i> , 1995, 103, 624-635.	0.7	132
53	Factors affecting the success of next-generation sequencing in cytology specimens. <i>Cancer Cytopathology</i> , 2015, 123, 659-668.	2.5	132
54	The Immunophenotype of Adult Acute Myeloid Leukemia: High Frequency of Lymphoid Antigen Expression and Comparison of Immunophenotype, French-American-British Classification, and Karyotypic Abnormalities. <i>American Journal of Clinical Pathology</i> , 1998, 109, 211-220.	0.7	131

#	ARTICLE	IF	CITATIONS
55	Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. <i>Blood</i> , 2017, 129, 1658-1668.	1.4	131
56	Oncocytoid Renal Cell Carcinoma After Neuroblastoma: A Report of Four Cases of a Distinct Clinicopathologic Entity. <i>American Journal of Surgical Pathology</i> , 1999, 23, 772.	3.8	128
57	Cytogenetic Findings in Lymphoplasmacytic Lymphoma /Waldenström Macroglobulinemia. <i>American Journal of Clinical Pathology</i> , 2001, 116, 543-549.	0.7	126
58	Lymphoid Infiltrates of the Orbit and Conjunctiva. <i>American Journal of Surgical Pathology</i> , 1989, 13, 459-471.	3.8	125
59	TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. <i>American Journal of Hematology</i> , 2013, 88, 1055-1061.	4.2	125
60	Oncocytic Adrenocortical Neoplasms. <i>American Journal of Surgical Pathology</i> , 1998, 22, 603-614.	3.8	125
61	Lymphoproliferative Lesions in Patients with Common Variable Immunodeficiency Syndrome. <i>American Journal of Surgical Pathology</i> , 1992, 16, 1170-1182.	3.8	124
62	Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. <i>Oncogene</i> , 2003, 22, 5399-5407.	5.8	123
63	The Diagnostic Utility of the Keratin Profiles of Hepatocellular Carcinoma and Cholangiocarcinoma. <i>American Journal of Surgical Pathology</i> , 1988, 12, 187-197.	3.8	120
64	Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. <i>Modern Pathology</i> , 2017, 30, 499-508.	5.6	120
65	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries. <i>Clinical Cancer Research</i> , 2014, 20, 2338-2349.	7.1	119
66	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 644-657.	3.2	119
67	Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. <i>Leukemia Research</i> , 2015, 39, 348-354.	1.1	117
68	New Developments in the Pathologic Diagnosis of Adrenal Cortical Neoplasms: A Review. <i>American Journal of Clinical Pathology</i> , 1992, 97, 73-83.	0.7	116
69	T-Cell Lymphoblastic Lymphoma With Eosinophilia Associated With Subsequent Myeloid Malignancy. <i>American Journal of Surgical Pathology</i> , 1992, 16, 236-245.	3.8	114
70	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2014, 27, 958-971.	5.6	114
71	Global Adverse Event Reports of Breast Implant-Associated ALCL: An International Review of 40 Government Authority Databases. <i>Plastic and Reconstructive Surgery</i> , 2017, 139, 1029-1039.	1.6	114
72	Lymphoblastic lymphoma presenting in cutaneous sites. <i>Journal of the American Academy of Dermatology</i> , 1991, 25, 1023-1031.	1.2	113

#	ARTICLE	IF	CITATIONS
73	Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. <i>Modern Pathology</i> , 2009, 22, 1023-1031.	5.6	112
74	Sinus Histiocytosis with Massive Lymphadenopathy and Malignant Lymphoma Involving the Same Lymph Node: A Report of Four Cases and Review of the Literature. <i>Modern Pathology</i> , 2000, 13, 414-419.	5.6	110
75	Molecular characterization of <i>de novo</i> Philadelphia chromosome-positive acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 138-144.	1.3	110
76	Diffuse large B-cell lymphoma variants: an update. <i>Pathology</i> , 2020, 52, 53-67.	0.7	110
77	Activation of Mammalian Target of Rapamycin Signaling Promotes Cell Cycle Progression and Protects Cells from Apoptosis in Mantle Cell Lymphoma. <i>American Journal of Pathology</i> , 2006, 169, 2171-2180.	4.0	109
78	Mantle Cell Lymphoma with 8q24 Chromosomal Abnormalities: a Report of 5 Cases with Blastoid Features. <i>Modern Pathology</i> , 2002, 15, 1266-1272.	5.6	108
79	T-Lymphoblastic Leukemia/Lymphoma. <i>American Journal of Clinical Pathology</i> , 2015, 144, 411-422.	0.7	108
80	Characterization of 4 Mantle Cell Lymphoma Cell Lines. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 424-431.	2.5	108
81	Localized non-Hodgkin lymphoma involving the thyroid gland. <i>Cancer</i> , 2001, 91, 629-635.	4.0	107
82	Hepatosplenic gamma/delta T-Cell Lymphoma in Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2001, 116, 410-419.	0.7	107
83	Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. <i>Blood</i> , 2018, 132, 544-547.	1.4	106
84	Breast implant-associated anaplastic large cell lymphoma: a review. <i>Modern Pathology</i> , 2019, 32, 166-188.	5.6	106
85	Lymphoid Neoplasms Associated With IgM Paraprotein. <i>American Journal of Clinical Pathology</i> , 2005, 123, 200-205.	0.7	102
86	Acute Lymphoblastic Leukemia: Survey of Immunophenotype, French-American-British Classification, Frequency of Myeloid Antigen Expression, and Karyotypic Abnormalities in 210 Pediatric and Adult Cases. <i>American Journal of Clinical Pathology</i> , 1999, 111, 467-476.	0.7	101
87	Mature B-Cell Leukemias With More Than 55% Prolymphocytes. <i>American Journal of Clinical Pathology</i> , 2001, 115, 571-581.	0.7	101
88	Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. <i>Blood</i> , 2010, 115, 1985-1992.	1.4	100
89	bcl-2 Rearrangements in <i>de novo</i> diffuse large cell lymphoma. Association with distinctive clinical features. <i>Cancer</i> , 1993, 72, 231-236.	4.0	99
90	Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2005, 132, 051220022257008.	2.7	99

#	ARTICLE	IF	CITATIONS
91	Non-Hodgkin's Lymphoma Involving the Gynecologic Tract: A Review of 88 Cases. <i>Advances in Anatomic Pathology</i> , 2001, 8, 200-217.	4.3	98
92	Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. <i>Modern Pathology</i> , 2004, 17, 954-961.	5.6	98
93	Extramedullary Manifestations of Myeloid Neoplasms. <i>American Journal of Clinical Pathology</i> , 2015, 144, 219-239.	0.7	98
94	Nonmyeloablative allogeneic transplantation with or without ⁹⁰ yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. <i>Blood</i> , 2012, 119, 6373-6378.	1.4	97
95	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 2401-2416.	2.0	97
96	Acute Myeloid Leukemia With t(6;9)(p23;q34) Is Associated With Dysplasia and a High Frequency of <i>FLT3</i> Gene Mutations. <i>American Journal of Clinical Pathology</i> , 2004, 122, 348-358.	0.7	96
97	Overview of the Role of Molecular Methods in the Diagnosis of Malignant Lymphomas. <i>Archives of Pathology and Laboratory Medicine</i> , 1999, 123, 1189-1207.	2.5	96
98	Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification. <i>Modern Pathology</i> , 2011, 24, 375-383.	5.6	95
99	Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors. <i>American Journal of Clinical Pathology</i> , 2016, 145, 222-237.	0.7	95
100	Cyclin D1 Immunohistochemical Staining Is Useful in Distinguishing Mantle Cell Lymphoma From Other Low-Grade B-Cell Neoplasms in Bone Marrow. <i>American Journal of Clinical Pathology</i> , 1997, 108, 302-307.	0.7	94
101	<i>DDX41</i> mutations in myeloid neoplasms are associated with male gender, <i>TP53</i> mutations and high-risk disease. <i>American Journal of Hematology</i> , 2019, 94, 757-766.	4.2	92
102	Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorders Arising in Immunodeficient Patients Previously Treated With Fludarabine for Low-Grade B-Cell Neoplasms. <i>American Journal of Surgical Pathology</i> , 2002, 26, 630-636.	3.8	91
103	BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. <i>Blood</i> , 2002, 100, 3935-3941.	1.4	91
104	<i>FLT3</i> and <i>NPM1</i> Mutations in Myelodysplastic Syndromes. <i>American Journal of Clinical Pathology</i> , 2011, 135, 62-69.	0.7	91
105	Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. <i>Journal of Hematology and Oncology</i> , 2014, 7, 74.	17.3	91
106	A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. <i>Blood</i> , 2014, 124, 3768-3771.	1.4	91
107	Anaplastic Large Cell Lymphoma Involving the Breast: A Clinicopathologic Study of 6 Cases and Review of the Literature. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 1383-1390.	2.5	91
108	Differential Expression of BCL-2 Family Proteins in ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma of T/Null-Cell Lineage. <i>American Journal of Pathology</i> , 2001, 159, 527-535.	4.0	90

#	ARTICLE	IF	CITATIONS
109	Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. <i>Blood</i> , 2005, 105, 827-829.	1.4	90
110	Chunking as the result of an efficiency computation trade-off. <i>Nature Communications</i> , 2016, 7, 12176.	12.8	90
111	Intravascular Large B-Cell Lymphoma: A Report of Five Cases Initially Diagnosed by Bone Marrow Biopsy. <i>American Journal of Clinical Pathology</i> , 1999, 112, 248-255.	0.7	89
112	Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-Cell lymphoma. <i>Modern Pathology</i> , 2009, 22, 1312-1320.	5.6	89
113	High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. <i>Haematologica</i> , 2007, 92, 1297-1301.	3.4	88
114	Stage I Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 1993, 17, 275-286.	3.8	87
115	Grading of renal cell carcinoma. <i>Cancer</i> , 1997, 80, 990-991.	4.0	87
116	Mantle Cell Lymphoma Involving Skin. <i>American Journal of Surgical Pathology</i> , 2002, 26, 1312-1318.	3.8	87
117	Epstein-Barr Virus Is Infrequently Identified in Non-Hodgkin's Lymphomas Associated with Hodgkin's Disease. <i>American Journal of Surgical Pathology</i> , 1994, 18, 48-61.	3.8	86
118	Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia. <i>Advances in Anatomic Pathology</i> , 2005, 12, 246-255.	4.3	86
119	<i>MYC</i> / <i>BCL6</i> double-hit lymphoma (<i>DHL</i>): a tumour associated with an aggressive clinical course and poor prognosis. <i>Histopathology</i> , 2016, 68, 1090-1098.	3.0	85
120	Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease. <i>Modern Pathology</i> , 2014, 27, 823-831.	5.6	84
121	A Novel Four-Color PCR Assay to Assess T-Cell Receptor Gamma Gene Rearrangements in Lymphoproliferative Lesions. <i>American Journal of Clinical Pathology</i> , 2001, 116, 17-24.	0.7	83
122	The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma. <i>British Journal of Haematology</i> , 2017, 176, 750-758.	2.7	83
123	Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 293-305.	3.8	83
124	The T-Cell Chemokine Receptor CXCR3 Is Expressed Highly in Low-Grade Mycosis Fungoides. <i>American Journal of Clinical Pathology</i> , 2001, 115, 413-421.	0.7	82
125	Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. <i>Haematologica</i> , 2009, 94, 29-37.	3.4	82
126	Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. <i>Human Pathology</i> , 2018, 74, 5-16.	2.3	82

#	ARTICLE	IF	CITATIONS
127	Neurofibroma and Cellular Neurofibroma With Atypia. American Journal of Surgical Pathology, 1997, 21, 1443-1449.	3.8	81
128	The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood, 2012, 119, 4017-4025.	1.4	80
129	CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Disease: Associations With Presenting Features and Clinical Outcome. Journal of Clinical Oncology, 2002, 20, 1278-1287.	5.7	79
130	Kikuchi-Fujimoto Lymphadenitis. Advances in Anatomic Pathology, 2003, 10, 204-211.	4.3	78
131	<i>MYC</i> translocation in chronic lymphocytic leukaemia is associated with increased polymphocytes and a poor prognosis. British Journal of Haematology, 2008, 142, 36-44.	2.7	78
132	Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chromosomal abnormalities in <i>SM</i> and <i>AHNMD</i> components. American Journal of Hematology, 2013, 88, 219-224.	4.2	78
133	A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors. Journal of Molecular Diagnostics, 2017, 19, 255-264.	2.9	78
134	Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer, 1997, 80, 1768-1775.	4.0	77
135	B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas. Modern Pathology, 2015, 28, 208-217.	5.6	77
136	Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2018, 8, 351.	2.9	76
137	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer, 2019, 125, 559-574.	4.0	75
138	Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget, 2015, 6, 5615-5633.	2.0	75
139	Immunomodulator agent-related lymphoproliferative disorders. Modern Pathology, 2009, 22, 1532-1540.	5.6	74
140	Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clinical Cancer Research, 2018, 24, 3967-3980.	7.1	74
141	Immunophenotypic Diagnosis of Non-Hodgkin's Lymphoma in Paraffin Sections: Co-Expression of L60 (Leu-22) and L26 Antigens Correlates with Malignant Histologic Findings. American Journal of Clinical Pathology, 1989, 91, 579-583.	0.7	72
142	MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma. Advances in Anatomic Pathology, 2013, 20, 315-326.	4.3	72
143	Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. Clinical Cancer Research, 2015, 21, 2644-2651.	7.1	72
144	P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. Modern Pathology, 2017, 30, 194-203.	5.6	72

#	ARTICLE	IF	CITATIONS
145	Waldenstrom Macroglobulinemia Involving Extramedullary Sites. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1104-1113.	3.8	71
146	Therapy-Related Acute Myeloid Leukemia With t(8;21) (q22;q22) Shares Many Features With De Novo Acute Myeloid Leukemia With t(8;21)(q22;q22) but Does Not Have a Favorable Outcome. <i>American Journal of Clinical Pathology</i> , 2009, 131, 647-655.	0.7	71
147	Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. <i>Blood Reviews</i> , 2018, 32, 8-28.	5.9	71
148	Chromosomal Translocations Involved in Non-Hodgkin Lymphomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 1148-1160.	2.5	71
149	Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. <i>American Journal of Hematology</i> , 2014, 89, 813-818.	4.2	70
150	Pagetoid Bowen Disease. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 427-430.	2.5	70
151	JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. <i>Modern Pathology</i> , 2005, 18, 1365-1370.	5.6	69
152	Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. <i>Cancer</i> , 2016, 122, 559-564.	4.0	69
153	Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. <i>Cancer</i> , 2012, 118, 2879-2888.	4.0	68
154	Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1132-1139.	3.8	68
155	Prognostic Factors of Hepatosplenic T-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 676-688.	3.8	68
156	Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 472-477.	1.4	68
157	Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. <i>Haematologica</i> , 2017, 102, 1661-1670.	3.4	68
158	Clusterin Expression in Malignant Lymphomas: A Survey of 266 Cases. <i>Modern Pathology</i> , 2002, 15, 1221-1226.	5.6	67
159	Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Modern Pathology</i> , 2012, 25, 237-245.	5.6	67
160	Differential Expression of CD200 in B-Cell Neoplasms by Flow Cytometry Can Assist in Diagnosis, Subclassification, and Bone Marrow Staging. <i>American Journal of Clinical Pathology</i> , 2014, 142, 837-844.	0.7	67
161	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018, 20, 574-593.	5.3	67
162	Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. <i>Cancer</i> , 2004, 101, 332-336.	4.0	66

#	ARTICLE	IF	CITATIONS
163	Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1948-1954.	2.0	66
164	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 3083-3100.	1.4	66
165	Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. <i>Clinical Cancer Research</i> , 2018, 24, 521-531.	7.1	66
166	Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. <i>Cancer</i> , 2009, 115, 5481-5489.	4.0	65
167	Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. <i>Leukemia and Lymphoma</i> , 2010, 51, 1217-1224.	1.3	65
168	Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor- κ B-inducing kinase while activating both canonical and alternative nuclear factor- κ B pathways. <i>Blood</i> , 2011, 117, 200-210.	1.4	65
169	Extracavitary/solid variant of primary effusion lymphoma. <i>Annals of Diagnostic Pathology</i> , 2012, 16, 441-446.	1.3	65
170	Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. <i>Cancer</i> , 2012, 118, 112-117.	4.0	65
171	Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. <i>Cancer</i> , 2012, 118, 1566-1573.	4.0	65
172	Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling. <i>Modern Pathology</i> , 2018, 31, 1036-1045.	5.6	65
173	Lymphomas Involving the Pleura: A Clinicopathologic Study of 34 Cases Diagnosed By Pleural Biopsy. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1497-1502.	2.5	65
174	Neutrophil-Rich Anaplastic Large Cell Lymphoma of T-Cell Lineage. <i>American Journal of Clinical Pathology</i> , 2000, 114, 478-482.	0.7	63
175	Mucoepidermoid Carcinoma Involving Warthin Tumor. <i>American Journal of Clinical Pathology</i> , 2000, 114, 564-570.	0.7	63
176	CD4 ⁻ CD8 ⁻ 'Double-Negative' Cutaneous T-Cell Lymphomas Share Common Histologic Features and an Aggressive Clinical Course. <i>American Journal of Surgical Pathology</i> , 2002, 26, 225-231.	3.8	63
177	Crystal-storing histiocytosis: a clinicopathological study of 13 cases. <i>Histopathology</i> , 2016, 68, 482-491.	3.0	63
178	Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. <i>Pathology</i> , 2020, 52, 154-165.	0.7	63
179	Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta ($\gamma\delta$) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous $\gamma\delta$ T-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 204-215.	3.8	62
180	Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1429-1437.	3.8	62

#	ARTICLE	IF	CITATIONS
181	The Heidelberg classification of renal cell tumours. <i>Journal of Pathology</i> , 1997, 183, 131-133.	4.4	62
182	Non-Hodgkin's Lymphomas Arising in Patients Successfully Treated for Hodgkin's Disease. <i>American Journal of Surgical Pathology</i> , 1992, 16, 885-895.	3.8	61
183	Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. <i>Haematologica</i> , 2012, 97, 1080-1084.	3.4	61
184	Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 5113-5123.	7.1	61
185	Lymphohistiocytoid Mesothelioma. <i>American Journal of Clinical Pathology</i> , 2000, 113, 649-654.	0.7	60
186	Absence of Epstein-Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria. <i>Human Pathology</i> , 2004, 35, 455-459.	2.3	60
187	Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. <i>British Journal of Haematology</i> , 2017, 178, 403-412.	2.7	60
188	Cyclin D1 Overexpression in Spitz Nevi: An Immunohistochemical Study. <i>American Journal of Dermatopathology</i> , 1999, 21, 115-120.	0.6	60
189	Activating FLT3 Mutations Are Detectable in Chronic and Blast Phases of Chronic Myeloproliferative Disorders Other Than Chronic Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2006, 126, 530-533.	0.7	59
190	Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor β chain antibodies and its application in blood staging. <i>Modern Pathology</i> , 2010, 23, 284-295.	5.6	59
191	Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 305-311.	3.4	59
192	Myeloid Sarcoma Involving the Breast. <i>Archives of Pathology and Laboratory Medicine</i> , 2005, 129, 32-38.	2.5	59
193	Apoptotic Rate in Peripheral T-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2002, 118, 328-334.	0.7	58
194	Cellular DNA Profiles of Benign and Malignant Adrenocortical Tumors. <i>American Journal of Surgical Pathology</i> , 1990, 14, 948-955.	3.8	57
195	Cytogenetic Findings in Mantle Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2001, 116, 886-892.	0.7	57
196	Aberrant Underexpression of CD81 in Precursor B-Cell Acute Lymphoblastic Leukemia. <i>American Journal of Clinical Pathology</i> , 2009, 132, 692-698.	0.7	57
197	Hematolymphoid Neoplasms Associated With Rearrangements of PDGFRA, PDGFRB, and FGFR1. <i>American Journal of Clinical Pathology</i> , 2015, 144, 377-392.	0.7	57
198	PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 372-381.	2.3	57

#	ARTICLE	IF	CITATIONS
199	NTRK3 overexpression in undifferentiated sarcomas with YWHAE and BCOR genetic alterations. <i>Modern Pathology</i> , 2020, 33, 1341-1349.	5.6	57
200	<i>TP53</i> copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. <i>Blood</i> , 2022, 140, 58-72.	1.4	57
201	Isothermal Multiple Displacement Amplification. <i>Journal of Molecular Diagnostics</i> , 2004, 6, 236-242.	2.9	56
202	The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases. <i>British Journal of Haematology</i> , 2007, 136, 220-228.	2.7	56
203	Sole rearrangement but not amplification of <i>MYC</i> is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. <i>British Journal of Haematology</i> , 2016, 175, 631-640.	2.7	56
204	A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2018, 54, 61-66.	1.9	56
205	Characteristics and Treatment of Advanced Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 41S-50S.	1.6	55
206	Expression of LFA-1 in non-hodgkin's lymphoma. <i>Cancer</i> , 1989, 63, 255-259.	4.0	54
207	Dissolution of the Lymphoid Follicle Is a Feature of the HHV8+ Variant of Plasma Cell Castleman's Disease. <i>American Journal of Surgical Pathology</i> , 2003, 27, 91-100.	3.8	54
208	Microscopic Diffuse Large B-Cell Lymphoma (DLBCL) Occurring in Pseudocysts. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1074-1080.	3.8	54
209	Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. <i>Modern Pathology</i> , 2014, 27, 681-689.	5.6	54
210	Reticulum Cell Sarcoma of Lymph Node with Mixed Dendritic and Fibroblastic Features. <i>Modern Pathology</i> , 2001, 14, 1059-1067.	5.6	53
211	Pediatric Therapy-related Myelodysplastic Syndrome/Acute Myeloid Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 803-811.	0.6	53
212	Nonallele Specific Silencing of Ataxin-7 Improves Disease Phenotypes in a Mouse Model of SCA7. <i>Molecular Therapy</i> , 2014, 22, 1635-1642.	8.0	53
213	TC2 and NF- κ B Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy. <i>Cancer Research</i> , 2016, 76, 6410-6423.	0.9	53
214	CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 749-755.	3.4	53
215	Immunophenotypic Profile of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia. <i>American Journal of Clinical Pathology</i> , 2005, 124, 414-420.	0.7	53
216	Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 489-495.	3.8	52

#	ARTICLE	IF	CITATIONS
217	Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. <i>Cancer</i> , 2006, 107, 1844-1851.	4.0	52
218	N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. <i>Modern Pathology</i> , 2012, 25, 231-236.	5.6	52
219	High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. <i>American Journal of Surgical Pathology</i> , 2016, 40, 253-261.	3.8	52
220	B-Cell Chronic Lymphocytic Leukemia Followed by High Grade T-Cell Lymphoma: An Unusual Variant of Richter's Syndrome. <i>American Journal of Clinical Pathology</i> , 1995, 103, 348-352.	0.7	51
221	Adrenal Cortical Tumors Clinically Mimicking Pheochromocytoma. <i>American Journal of Clinical Pathology</i> , 1995, 104, 382-390.	0.7	51
222	CD117 Expression Is a Sensitive but Nonspecific Predictor of FLT3 Mutation in T Acute Lymphoblastic Leukemia and T/Myeloid Acute Leukemia. <i>American Journal of Clinical Pathology</i> , 2012, 137, 213-219.	0.7	51
223	MYC Cytogenetic Status Correlates With Expression and Has Prognostic Significance in Patients With MYC/BCL2 Protein Double-positive Diffuse Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1250-1258.	3.8	51
224	Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 3593-3605.	7.1	51
225	Mantle Cell Lymphoma With MYC Rearrangement. <i>American Journal of Surgical Pathology</i> , 2017, 41, 216-224.	3.8	51
226	Pure erythroid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 292-296.	4.2	51
227	MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. <i>Modern Pathology</i> , 2018, 31, 1470-1478.	5.6	51
228	Non-Hodgkin's Lymphoma Involving the Vagina. <i>American Journal of Surgical Pathology</i> , 2000, 24, 719-725.	3.8	50
229	Phenotypic Modulation of the Stromal Reticular Network in Normal and Neoplastic Lymph Nodes. <i>American Journal of Pathology</i> , 2003, 163, 165-174.	4.0	50
230	Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. <i>Modern Pathology</i> , 2012, 25, 1405-1412.	5.6	50
231	Follicle Center Lymphoma and Warthin Tumor Involving the Same Anatomic Site. <i>American Journal of Clinical Pathology</i> , 2000, 113, 113-119.	0.7	49
232	Sinusoidal CD30-Positive Large B-Cell Lymphoma: A Morphologic Mimic of Anaplastic Large Cell Lymphoma. <i>Modern Pathology</i> , 2000, 13, 223-228.	5.6	49
233	Hodgkin Lymphoma Involving Waldeyer Ring. <i>American Journal of Clinical Pathology</i> , 2005, 123, 651-656.	0.7	49
234	The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009, 14, 336-347.	4.8	49

#	ARTICLE	IF	CITATIONS
235	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015, 28, 1555-1573.	5.6	49
236	Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2017, 30, 1688-1697.	5.6	49
237	Flow Cytometric Immunophenotyping of Anaplastic Large Cell Lymphoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 49-56.	2.5	49
238	Non-Hodgkin's Lymphoma Involving the Vulva. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 236-242.	1.5	48
239	Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. <i>Cancer</i> , 2007, 109, 77-83.	4.0	48
240	t(8;13)-positive Bilineal Lymphomas. <i>American Journal of Surgical Pathology</i> , 2008, 32, 14-20.	3.8	48
241	CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. <i>Modern Pathology</i> , 2018, 31, 327-336.	5.6	48
242	High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma. <i>Modern Pathology</i> , 2019, 32, 48-58.	5.6	48
243	T-cell clones of uncertain significance are highly prevalent and show close resemblance to T-cell large granular lymphocytic leukemia. Implications for laboratory diagnostics. <i>Modern Pathology</i> , 2020, 33, 2046-2057.	5.6	48
244	The Cells of Giant Cell Tumor of Tendon Sheath Resemble Osteoclasts. <i>American Journal of Surgical Pathology</i> , 1988, 12, 444-452.	3.8	47
245	Anaplastic Large Cell Lymphomas Presented as Bone Lesions: A Clinicopathologic Study of Six Cases and Review of the Literature. <i>Modern Pathology</i> , 2000, 13, 1143-1149.	5.6	47
246	Leukemic Mantle Cell Lymphoma: Clinical and Pathologic Spectrum of Twenty-Three Cases. <i>Modern Pathology</i> , 2001, 14, 1133-1140.	5.6	47
247	International prognostic index-based outcomes for diffuse large B-cell lymphomas. <i>Cancer</i> , 2002, 94, 3083-3088.	4.0	47
248	De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification. <i>Modern Pathology</i> , 2011, 24, 384-389.	5.6	47
249	Distinguishing Between Hepatosplenic T-cell Lymphoma and $\hat{t}(3;3)$ T-cell Large Granular Lymphocytic Leukemia. <i>American Journal of Surgical Pathology</i> , 2017, 41, 82-93.	3.8	47
250	<i>c-MYC</i> -driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. <i>Oncotarget</i> , 2015, 6, 38591-38616.	2.0	47
251	Acute Erythroid Leukemia. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 1261-1270.	2.5	47
252	Detection of Chromosome 11q13 Breakpoints by Interphase Fluorescence In Situ Hybridization. <i>American Journal of Clinical Pathology</i> , 2000, 114, 248-257.	0.7	46

#	ARTICLE	IF	CITATIONS
253	Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 678-686.	2.9	46
254	Residual Monotypic Plasma Cells in Patients With Waldenström Macroglobulinemia After Therapy. <i>American Journal of Clinical Pathology</i> , 2011, 135, 365-373.	0.7	46
255	High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with <i>BCL2</i> and/or <i>MYC</i> gene rearrangements and a poor prognosis. <i>Histopathology</i> , 2012, 61, 945-954.	3.0	46
256	Chronic myelomonocytic leukemia with nucleophosmin (<i>NPM1</i>) mutation. <i>European Journal of Haematology</i> , 2016, 96, 65-71.	2.2	46
257	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. <i>Blood Advances</i> , 2020, 4, 1038-1050.	5.3	46
258	Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Hodgkin Disease. <i>American Journal of Clinical Pathology</i> , 2001, 116, 34-40.	0.7	45
259	Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with <i>NPM1</i> mutation and is not predictive of prognosis. <i>Cancer</i> , 2009, 115, 4737-4744.	4.0	45
260	<i>TP53</i> overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. <i>British Journal of Haematology</i> , 2015, 171, 91-99.	2.7	45
261	Primary Cutaneous Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2002, 117, 574-580.	0.7	44
262	Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma. <i>Modern Pathology</i> , 2007, 20, 1-7.	5.6	44
263	The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms. <i>Frontiers in Oncology</i> , 2013, 3, 169.	2.9	44
264	Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm. <i>Modern Pathology</i> , 2014, 27, 1137-1143.	5.6	44
265	Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in <i>SETBP1</i> , <i>SRSF2</i> , <i>ASXL1</i> and <i>NRAS</i> . <i>Oncotarget</i> , 2016, 7, 14251-14258.	2.0	44
266	p53 Expression in Reed-Sternberg Cells Does Not Correlate With Gene Mutations in Hodgkin's Disease. <i>American Journal of Clinical Pathology</i> , 1996, 106, 728-738.	0.7	43
267	Non-Hodgkin's Lymphoma Affecting the Testis: Is It Curable with Doxorubicin-Based Therapy?. <i>Clinical Lymphoma and Myeloma</i> , 2001, 2, 40-46.	2.3	43
268	Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin's Disease Treated with Radiotherapy. <i>Leukemia and Lymphoma</i> , 2004, 45, 2085-2092.	1.3	43
269	c-Jun Expression and Activation are Restricted to CD30+ Lymphoproliferative Disorders. <i>American Journal of Surgical Pathology</i> , 2007, 31, 447-453.	3.8	43
270	Analysis of Aurora kinase A expression in CD34+ blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. <i>Journal of Hematopathology</i> , 2009, 2, 2-8.	0.5	43

#	ARTICLE	IF	CITATIONS
271	Myelodysplastic Syndrome With inv(3)(q21q26.2) or t(3;3)(q21;q26.2) Has a High Risk for Progression to Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2011, 136, 282-288.	0.7	43
272	Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4529-4540.	1.4	43
273	Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1036-1043.	4.2	43
274	Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. <i>Haematologica</i> , 2021, 106, 1047-1055.	3.4	43
275	Transformation of Follicular Lymphoma into CD30-Large Cell Lymphoma with Anaplastic Cytologic Features. <i>American Journal of Surgical Pathology</i> , 1997, 21, 528-536.	3.8	43
276	Overexpression of Mcl-1 in Anaplastic Large Cell Lymphoma Cell Lines and Tumors. <i>American Journal of Pathology</i> , 2002, 160, 2309-2310.	4.0	42
277	Marginal zone lymphomas. <i>Cancer</i> , 2010, 116, 4291-4298.	4.0	42
278	Survival Predictors in Acute Respiratory Distress Syndrome With Extracorporeal Membrane Oxygenation. <i>Annals of Thoracic Surgery</i> , 2015, 99, 243-250.	1.4	42
279	Chronic Myeloid Leukemia: Beyond BCR-ABL1. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 435-445.	2.3	42
280	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , 2019, 32, 741-754.	5.6	42
281	KSHV/HHV8-positive large B-cell lymphomas and associated diseases: a heterogeneous group of lymphoproliferative processes with significant clinicopathological overlap. <i>Modern Pathology</i> , 2020, 33, 18-28.	5.6	42
282	T-Cell Large Granular Lymphocyte Leukemia Associated With Myelodysplastic Syndrome. <i>American Journal of Clinical Pathology</i> , 2009, 131, 347-356.	0.7	41
283	Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?. <i>Haematologica</i> , 2012, 97, 919-925.	3.4	41
284	Myeloid Sarcoma of the Head and Neck Region. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1560-1568.	2.5	41
285	Indolent peripheral T-cell lymphoma involving the gastrointestinal tract. <i>Human Pathology</i> , 2014, 45, 421-426.	2.3	41
286	Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. <i>Modern Pathology</i> , 2016, 29, 1118-1142.	5.6	41
287	Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. <i>European Journal of Haematology</i> , 2017, 98, 415-421.	2.2	41
288	Primary Follicular Large Cell Lymphoma of the Testis in a Child. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 551-554.	2.5	41

#	ARTICLE	IF	CITATIONS
289	<i>bcl-2</i> Expression in Hodgkin's Disease: Correlation with the t(14; 18) Translocation and Epstein-Barr Virus. <i>American Journal of Clinical Pathology</i> , 1993, 99, 604-608.	0.7	40
290	The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumours. <i>British Journal of Haematology</i> , 2002, 117, 569-576.	2.7	40
291	Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. <i>Modern Pathology</i> , 2005, 18, 1343-1349.	5.6	40
292	Bone Marrow Involvement by Marginal Zone B-Cell Lymphomas of Different Types. <i>American Journal of Clinical Pathology</i> , 2008, 129, 714-722.	0.7	40
293	Utility of the World Health Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. <i>Modern Pathology</i> , 2009, 22, 50-57.	5.6	40
294	Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. <i>Cancer</i> , 2011, 117, 4009-4017.	4.0	40
295	Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2016, 145, 769-777.	0.7	40
296	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2017, 187, 1700-1716.	4.0	40
297	Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. <i>Modern Pathology</i> , 2017, 30, 1338-1366.	5.6	40
298	Nucleophosmin Gene Mutations in Acute Myeloid Leukemia. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1687-1692.	2.5	40
299	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 202-212.	5.7	40
300	Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. <i>Modern Pathology</i> , 2004, 17, 911-917.	5.6	39
301	Phosphorylated CXCR4 is associated with poor survival in adults with acute lymphoblastic leukemia. <i>Cancer</i> , 2011, 117, 4689-4695.	4.0	39
302	MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 162, 336-347.	2.7	39
303	Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. <i>Cancer</i> , 2018, 124, 2704-2713.	4.0	39
304	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. <i>Blood Advances</i> , 2018, 2, 1807-1816.	5.3	39
305	Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules. <i>Cancer Cytopathology</i> , 2019, 127, 146-160.	2.5	39
306	Splenic Marginal Zone Cell Lymphoma: An Immunophenotypic and Molecular Study of Five Cases. <i>American Journal of Clinical Pathology</i> , 1996, 105, 277-285.	0.7	38

#	ARTICLE	IF	CITATIONS
307	Splenic marginal zone lymphomas are characterized by loss of interstitial regions of chromosome 7q, 7q31.32 and 7q36.2 that include the protection of telomere 1 (<i>POT1</i>) and sonic hedgehog (<i>SHH</i>) genes. <i>British Journal of Haematology</i> , 2008, 142, 216-226.	2.7	38
308	Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma. <i>Modern Pathology</i> , 2013, 26, 1338-1345.	5.6	38
309	Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2631-2638.	1.3	38
310	Classical Hodgkin Lymphoma Arising in the Setting of Iatrogenic Immunodeficiency. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1290-1297.	3.8	38
311	Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. <i>Haematologica</i> , 2017, 102, 1511-1518.	3.4	38
312	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2489-2492.	7.3	38
313	Discrepancies in the Immunophenotype of Lymphoma Cells in Samples Obtained Simultaneously From Different Anatomic Sites. <i>American Journal of Clinical Pathology</i> , 2002, 117, 644-650.	0.7	37
314	c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma. <i>Blood</i> , 2006, 107, 2544-2547.	1.4	37
315	Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. <i>European Journal of Haematology</i> , 2006, 77, 387-394.	2.2	37
316	Expression of Bcl-2 in gastrointestinal stromal tumors. <i>Cancer</i> , 2006, 106, 1617-1623.	4.0	37
317	MALT Lymphoma Involving the Kidney. <i>American Journal of Clinical Pathology</i> , 2007, 128, 464-473.	0.7	37
318	HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. <i>Modern Pathology</i> , 2007, 20, 54-62.	5.6	37
319	Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features. <i>American Journal of Clinical Pathology</i> , 2011, 135, 686-696.	0.7	37
320	Rapid Detection and Quantitation of <i>BRAF</i> Mutations in Hairy Cell Leukemia Using a Sensitive Pyrosequencing Assay. <i>American Journal of Clinical Pathology</i> , 2012, 138, 153-156.	0.7	37
321	Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. <i>Blood Advances</i> , 2017, 1, 2541-2552.	5.3	37
322	Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. <i>Modern Pathology</i> , 2019, 32, 1698-1707.	5.6	37
323	Malignant Lymphomas of B-Cell Lineage with Marked Tissue Eosinophilia. <i>American Journal of Surgical Pathology</i> , 1994, 18, 347-356.	3.8	36
324	Surface Immunoglobulin Light Chain-Positive Acute Lymphoblastic Leukemia of FAB L1 or L2 Type: A Report of 6 Cases in Adults. <i>American Journal of Clinical Pathology</i> , 1998, 110, 143-149.	0.7	36

#	ARTICLE	IF	CITATIONS
325	Chronic Lymphocytic Leukemia With t(2;14)(p16;q32) Involves the <i>BCL11A</i> and <i>IgH</i> Genes and Is Associated With Atypical Morphologic Features and Unmutated <i>IgVH</i> Genes. <i>American Journal of Clinical Pathology</i> , 2009, 131, 663-670.	0.7	36
326	High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 991-994.	2.0	36
327	CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. <i>Leukemia and Lymphoma</i> , 2014, 55, 624-627.	1.3	36
328	Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 855-859.	2.0	36
329	Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. <i>Modern Pathology</i> , 2018, 31, 1717-1732.	5.6	36
330	Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. <i>Frontiers in Oncology</i> , 2019, 9, 107.	2.9	36
331	Prognostic impact of c-Rel nuclear expression and <i>REL</i> amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 23157-23180.	2.0	36
332	5' Exonuclease-Based Real-Time PCR Assays for Detecting the t(14;18)(q32;q21): A Survey of 162 Malignant Lymphomas and Reactive Specimens. <i>Modern Pathology</i> , 2000, 13, 661-666.	5.6	35
333	Anaplastic large cell lymphoma in leukemic phase: Extraordinarily high white blood cell count. <i>Pathology International</i> , 2009, 59, 345-353.	1.3	35
334	Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of $\hat{1}31$ T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With $\hat{1}31$ T-Cell Large Granular Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2015, 144, 607-619.	0.7	35
335	Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor α inhibitor therapy and literature review. <i>Annals of Diagnostic Pathology</i> , 2017, 26, 16-22.	1.3	35
336	TRIM44 promotes quiescent multiple myeloma cell occupancy and survival in the osteoblastic niche via HIF-1 α stabilization. <i>Leukemia</i> , 2019, 33, 469-486.	7.3	35
337	Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation. <i>Modern Pathology</i> , 2019, 32, 16-26.	5.6	35
338	Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma. <i>Haematologica</i> , 2021, 106, 1714-1724.	3.4	35
339	Mediastinal Lymphoblastic Lymphoma With an Immature B-Cell Immunophenotype. <i>American Journal of Surgical Pathology</i> , 1992, 16, 300-305.	3.8	34
340	Real-Time 5' Exonuclease-Based PCR Assay for Detection of the t(11;14)(q13;q32). <i>American Journal of Clinical Pathology</i> , 1999, 112, 524-530.	0.7	34
341	MALT1 gene rearrangements and NF- κ B activation involving p65 and p50 are absent or rare in primary MALT lymphomas of the breast. <i>Modern Pathology</i> , 2006, 19, 1402-1408.	5.6	34
342	The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. <i>Experimental Hematology</i> , 2006, 34, 1670-1679.	0.4	34

#	ARTICLE	IF	CITATIONS
343	Clonal Relationship of Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue Involving Different Sites. <i>American Journal of Clinical Pathology</i> , 2010, 134, 112-118.	0.7	34
344	Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature. <i>Human Pathology</i> , 2016, 58, 72-77.	2.3	34
345	Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 461-472.	3.2	34
346	Immune checkpoint blockade: Releasing the brake towards hematological malignancies. <i>Blood Reviews</i> , 2016, 30, 189-200.	5.9	34
347	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. <i>Oncotarget</i> , 2015, 6, 13933-13945.	2.0	34
348	Primary Cutaneous Non-Hodgkin's Lymphoma of Ann Arbor Stage I: Preferential Cutaneous Relapses but High Cure Rate With Doxorubicin-Based Therapy. <i>Journal of Clinical Oncology</i> , 2001, 19, 398-405.	5.7	33
349	Real-Time RT-PCR Assay for Quantifying Cyclin D1 mRNA in B-Cell Non-Hodgkin's Lymphomas. <i>Modern Pathology</i> , 2002, 15, 556-564.	5.6	33
350	Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. <i>British Journal of Haematology</i> , 2005, 130, 726-728.	2.7	33
351	High Serum Thymidine Kinase 1 Level Predicts Poorer Survival in Patients With Chronic Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2010, 134, 472-477.	0.7	33
352	Extranodal NK/T-cell Lymphoma, Nasal Type, Arising in Association With Saline Breast Implant. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1729-1734.	3.8	33
353	Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Cancer</i> , 2014, 120, 1818-1829.	4.0	33
354	Epstein-Barr virus-positive plasmacytoma in immunocompetent patients. <i>Histopathology</i> , 2015, 67, 225-234.	3.0	33
355	The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, 504-510.	4.2	33
356	Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1309-1321.	3.8	33
357	PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2020, 33, 324-333.	5.6	33
358	High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification. <i>Pathology</i> , 2020, 52, 68-77.	0.7	33
359	<i>BRAF</i> kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type <i>RAS</i> . <i>American Journal of Hematology</i> , 2014, 89, 499-504.	4.2	32
360	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with <i>NPM1</i> -mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 1054-1063.	2.7	32

#	ARTICLE	IF	CITATIONS
361	Low-Grade Renal Cell Carcinoma. American Journal of Surgical Pathology, 1987, 11, 633-642.	3.8	31
362	Transferrin receptor expression by non-hodgkin's lymphomas. Correlation with morphologic grade and survival. Cancer, 1988, 61, 1844-1851.	4.0	31
363	Small Lymphocytic Lymphoma with Perifollicular, Marginal Zone, or Interfollicular Distribution. Modern Pathology, 2000, 13, 1161-1166.	5.6	31
364	Pathologic Diagnosis of Mantle Cell Lymphoma. Clinical Lymphoma and Myeloma, 2000, 1, 197-206.	2.3	31
365	Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. Modern Pathology, 2008, 21, 1029-1036.	5.6	31
366	Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Modern Pathology, 2010, 23, 1113-1126.	5.6	31
367	Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. Leukemia Research, 2012, 36, 974-981.	1.1	31
368	Characteristics and Treatment of Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma Presenting with Aggressive Features. Plastic and Reconstructive Surgery, 2015, 136, 119-120.	1.6	31
369	Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. European Journal of Haematology, 2015, 95, 168-176.	2.2	31
370	Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. American Journal of Surgical Pathology, 2018, 42, 799-806.	3.8	31
371	Pioneers of Breast Implant-Associated Anaplastic Large Cell Lymphoma: History from Case Report to Global Recognition. Plastic and Reconstructive Surgery, 2019, 143, 7S-14S.	1.6	31
372	Primary Anaplastic Large Cell Lymphoma of the Small Intestine. American Journal of Clinical Pathology, 1999, 112, 696-701.	0.7	30
373	Apoptosis and Proliferation in Subcutaneous Panniculitis-Like T-Cell Lymphoma. Modern Pathology, 2002, 15, 625-631.	5.6	30
374	Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma. Leukemia, 2004, 18, 1872-1878.	7.3	30
375	LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. Blood, 2011, 117, 4076-4084.	1.4	30
376	The Impact of MYC Rearrangements and "Double Hit" Abnormalities in Diffuse Large B-Cell Lymphoma. Current Hematologic Malignancy Reports, 2013, 8, 243-252.	2.3	30
377	High Levels of Regulatory T Cells in Blood Are a Poor Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma. American Journal of Clinical Pathology, 2015, 144, 935-944.	0.7	30
378	De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis. Pediatric Hematology and Oncology, 2015, 32, 535-547.	0.9	30

#	ARTICLE	IF	CITATIONS
379	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. <i>Modern Pathology</i> , 2015, 28, 373-382.	5.6	30
380	Polyclonality in Sclerosing Angiomatoid Nodular Transformation of the Spleen. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1343-1351.	3.8	30
381	Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. <i>Leukemia Research</i> , 2018, 73, 86-94.	1.1	30
382	Geo-uniform consistency control module for preference similarity network hierarchical clustering based consensus model. <i>Knowledge-Based Systems</i> , 2018, 162, 103-114.	7.3	30
383	American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma. <i>Annals of Diagnostic Pathology</i> , 2019, 39, 105-110.	1.3	30
384	A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2020, 33, 367-379.	5.6	30
385	Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases. <i>Cancers</i> , 2021, 13, 878.	3.8	30
386	Acute Myeloid Leukemia With t(6;9)(p23;q34) Is Associated With Dysplasia and a High Frequency of flt3 Gene Mutations. <i>American Journal of Clinical Pathology</i> , 2004, 122, 348-358.	0.7	30
387	Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma. <i>Oncotarget</i> , 2016, 7, 38122-38132.	2.0	30
388	Mature B-Cell Leukemias With More Than 55% Prolymphocytes. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 305-309.	2.5	30
389	Presence of t(8;21)(q22;q22) in Myeloperoxidase-Positive, Myeloid Surface Antigen-Negative Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 1997, 107, 68-73.	0.7	29
390	Immunophenotype of Reed-Sternberg and Hodgkin's Cells in Sequential Biopsy Specimens of Hodgkin's Disease: A Paraffin-Section Immunohistochemical Study Using the Heat-Induced Epitope Retrieval Method. <i>American Journal of Clinical Pathology</i> , 1997, 108, 54-59.	0.7	29
391	Rapid Detection of IgH/BCL2 Rearrangement in Follicular Lymphoma by Interphase Fluorescence in Situ Hybridization with Bacterial Artificial Chromosome Probes. <i>Journal of Molecular Diagnostics</i> , 2002, 4, 144-149.	2.9	29
392	Diffuse Large B-Cell Lymphoma Occurring in Patients With Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia: Clinicopathologic Features of 12 Cases. <i>American Journal of Clinical Pathology</i> , 2003, 120, 246-253.	0.7	29
393	Retinoblastoma Protein Is Frequently Absent or Phosphorylated in Anaplastic Large-Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 164, 2259-2267.	4.0	29
394	Malignant Effusions Correlate With Poorer Prognosis in Patients With Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2015, 143, 707-715.	0.7	29
395	8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. <i>Leukemia Research</i> , 2018, 66, 73-78.	1.1	29
396	Cancer Therapy-associated Lymphoproliferative Disorders. <i>American Journal of Surgical Pathology</i> , 2018, 42, 116-129.	3.8	29

#	ARTICLE	IF	CITATIONS
397	Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. <i>Oncotarget</i> , 2018, 9, 10259-10271.	2.0	29
398	Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3939.	4.1	29
399	Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2019, 187, 307-318.	2.7	29
400	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	5.3	29
401	Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. <i>Modern Pathology</i> , 2021, 34, 2154-2167.	5.6	29
402	CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases. <i>Oncotarget</i> , 2018, 9, 11441-11450.	2.0	29
403	CD79b Expression in Chronic Lymphocytic Leukemia. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 561-566.	2.5	29
404	Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy. <i>British Journal of Haematology</i> , 2001, 112, 776-782.	2.7	28
405	Breast implant-associated anaplastic large cell lymphoma: a newly recognized entity that needs further refinement of its definition. <i>Leukemia and Lymphoma</i> , 2012, 53, 749-750.	1.3	28
406	Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. <i>Modern Pathology</i> , 2017, 30, 734-744.	5.6	28
407	Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 441-447.	4.2	28
408	Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1075-1079.	1.4	28
409	Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1235-1243.	3.8	28
410	Activation Status of the JAK/STAT3 Pathway in Mantle Cell Lymphoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2005, 129, 990-996.	2.5	28
411	Follicular Lymphoma in Staging Bone Marrow Specimens: Correlation of Histologic Findings With the Results of Flow Cytometry Immunophenotypic Analysis. <i>Archives of Pathology and Laboratory Medicine</i> , 2007, 131, 282-287.	2.5	28
412	Composite B-Cell and T-Cell Lymphoma: Coincidental Occurrence or Related Neoplasms? <i>American Journal of Clinical Pathology</i> , 1992, 98, 387-389.	0.7	27
413	Isolated Vulvar Langerhans Cell Histiocytosis: Report of Two Cases. <i>International Journal of Gynecological Pathology</i> , 2004, 23, 278-283.	1.5	27
414	CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. <i>Modern Pathology</i> , 2015, 28, 787-798.	5.6	27

#	ARTICLE	IF	CITATIONS
415	Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. <i>Oncotarget</i> , 2018, 9, 8441-8449.	2.0	27
416	Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. <i>Leukemia</i> , 2022, 36, 1343-1350.	7.3	27
417	Determination of Cyclin D1 and CD20 mRNA Levels by Real-Time Quantitative RT-PCR from Archival Tissue Sections of Mantle Cell Lymphoma and Other Non-Hodgkin's Lymphomas. <i>Journal of Molecular Diagnostics</i> , 2002, 4, 201-208.	2.9	26
418	Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. <i>Annals of Diagnostic Pathology</i> , 2006, 10, 263-268.	1.3	26
419	Clinicopathologic Features of CD5-Positive Nodal Marginal Zone Lymphoma. <i>American Journal of Clinical Pathology</i> , 2013, 140, 693-700.	0.7	26
420	Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart. <i>Histopathology</i> , 2015, 67, 625-635.	3.0	26
421	Implementation of next generation sequencing in clinical molecular diagnostic laboratories: advantages, challenges and potential. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 109-120.	0.6	26
422	Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults. <i>Annals of Hematology</i> , 2019, 98, 1149-1157.	1.8	26
423	CD5-negative Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1052-1060.	3.8	26
424	<i>i</i><i>i</i>MYC<i>i</i> rearrangement but not extra <i>i</i><i>i</i>MYC<i>i</i> copies is an independent prognostic factor in patients with mantle cell lymphoma. <i>Haematologica</i> , 2021, 106, 1381-1389.	3.4	26
425	The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. <i>PLoS ONE</i> , 2018, 13, e0191461.	2.5	26
426	Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 80599-80611.	2.0	26
427	Peripheral T-Cell Lymphoma Arising in the Liver. <i>American Journal of Clinical Pathology</i> , 2002, 118, 574-581.	0.7	25
428	Metastatic tumors in bone marrow: histopathology and advances in the biology of the tumor cells and bone marrow environment. <i>Annals of Diagnostic Pathology</i> , 2006, 10, 169-192.	1.3	25
429	Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494. <i>Clinical Cancer Research</i> , 2010, 16, 2435-2442.	7.1	25
430	Plasmablastic lymphoma involving the penis: a previously unreported location of a case with aberrant CD3 expression. <i>Pathology</i> , 2011, 43, 54-57.	0.7	25
431	Detection of High-Frequency and Novel DNMT3A Mutations in Acute Myeloid Leukemia by High-Resolution Melting Curve Analysis. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 336-345.	2.9	25
432	Differential expression of aurora-A kinase in T-cell lymphomas. <i>Modern Pathology</i> , 2013, 26, 640-647.	5.6	25

#	ARTICLE	IF	CITATIONS
433	The oncogenic <sc>JUNB</sc>/<sc>CD</sc>30 axis contributes to cell cycle deregulation in <sc>ALK</sc>+ anaplastic large cell lymphoma. British Journal of Haematology, 2014, 167, 514-523.	2.7	25
434	Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry. American Journal of Surgical Pathology, 2015, 39, 454-461.	3.8	25
435	Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. American Journal of Hematology, 2016, 91, E478-E479.	4.2	25
436	Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. Modern Pathology, 2018, 31, 307-312.	5.6	25
437	Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. PLoS ONE, 2018, 13, e0204218.	2.5	25
438	Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent <sc>CD</sc>33 expression and <i>in vitro</i> response to targeted <sc>CD</sc>33 therapy. British Journal of Haematology, 2019, 186, 538-548.	2.7	25
439	Assessment of penconazole exposure in winegrowers using urinary biomarkers. Environmental Research, 2019, 168, 54-61.	7.6	25
440	Ultra-Rapid Reporting of GENomic Targets (URGENTseq). Journal of Molecular Diagnostics, 2019, 21, 89-98.	2.9	25
441	Utilization of cytology smears improves success rates of RNAâ€based nextâ€generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathology, 2021, 129, 374-382.	2.5	25
442	Particle Trapping in Arbitrary Trajectories Using First-Order Bessel-Like Acoustic Beams. Physical Review Applied, 2021, 15, .	3.8	25
443	Myeloid Sarcoma Involving the Gynecologic Tract. American Journal of Clinical Pathology, 2006, 125, 783-790.	0.7	25
444	Cyclin D1 Expression in Dysplastic Nevi. Archives of Pathology and Laboratory Medicine, 2001, 125, 208-210.	2.5	25
445	Myeloid Sarcoma of the Urinary Bladder and Epididymis as a Primary Manifestation of Acute Myeloid Leukemia With inv(16). Archives of Pathology and Laboratory Medicine, 2006, 130, 862-866.	2.5	25
446	My 4 Antibody Staining of Non-Hodgkin's Lymphomas. American Journal of Clinical Pathology, 1991, 95, 363-368.	0.7	24
447	Hodgkinâ€™s Disease of the Esophagus. American Journal of Clinical Pathology, 1997, 108, 593-598.	0.7	24
448	Improved detection of clonality in cutaneous T-cell lymphomas using laser capture microdissection. Journal of Cutaneous Pathology, 2003, 30, 486-491.	1.4	24
449	BCL-3 overexpression in anaplastic lymphoma kinaseâ€positive anaplastic large cell lymphoma. Blood, 2003, 102, 1146-1147.	1.4	24
450	Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Modern Pathology, 2004, 17, 946-953.	5.6	24

#	ARTICLE	IF	CITATIONS
451	Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24). <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 37-42.	0.9	24
452	Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML. <i>PLoS ONE</i> , 2012, 7, e41485.	2.5	24
453	Genomic Variation by Whole-Genome SNP Mapping Arrays Predicts Time-to-Event Outcome in Patients with Chronic Lymphocytic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 196-209.	2.9	24
454	The Utility of BRAF V600E Mutation-Specific Antibody VE1 for the Diagnosis of Hairy Cell Leukemia. <i>American Journal of Clinical Pathology</i> , 2015, 143, 120-125.	0.7	24
455	Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. <i>Modern Pathology</i> , 2015, 28, 1225-1235.	5.6	24
456	Myeloid neoplasms with concurrent <i>BCR-ABL1</i> and <i>CBFB</i> rearrangements: A series of 10 cases of a clinically aggressive neoplasm. <i>American Journal of Hematology</i> , 2017, 92, 520-528.	4.2	24
457	Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. <i>Blood Advances</i> , 2018, 2, 1334-1343.	5.3	24
458	CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis. <i>Human Pathology</i> , 2019, 89, 71-80.	2.3	24
459	Myeloid/lymphoid neoplasms with FLT3 rearrangement. <i>Modern Pathology</i> , 2021, 34, 1673-1685.	5.6	24
460	Expression of CD2 in Acute Promyelocytic Leukemia Correlates With Short Form of PML-RAR α Transcripts and Poorer Prognosis. <i>American Journal of Clinical Pathology</i> , 2004, 121, 402-407.	0.7	24
461	Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. <i>PLoS ONE</i> , 2017, 12, e0181968.	2.5	24
462	Natural Killer Cell Lymphoma Involving the Gynecologic Tract. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 1510-1513.	2.5	24
463	Translocation (3;8)(q26;q24): a recurrent chromosomal abnormality in myelodysplastic syndrome and acute myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006, 166, 82-85.	0.9	23
464	Anaplastic large cell lymphoma: another entity in the differential diagnosis of small round blue cell tumors. <i>Annals of Diagnostic Pathology</i> , 2009, 13, 413-427.	1.3	23
465	HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis. <i>Modern Pathology</i> , 2010, 23, 381-391.	5.6	23
466	Potential therapeutic biomarkers in plasma cell myeloma: A flow cytometry study. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 222-228.	1.6	23
467	Plasma Cell Enrichment Enhances Detection of High-Risk Cytogenomic Abnormalities by Fluorescence In Situ Hybridization and Improves Risk Stratification of Patients With Plasma Cell Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 625-631.	2.5	23
468	Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. <i>Blood</i> , 2015, 125, 3360-3363.	1.4	23

#	ARTICLE	IF	CITATIONS
469	SOX11-negative Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 710-716.	3.8	23
470	Utility of combining antigranulocyte with antileukocyte antibodies in differentiating Hodgkin's disease from non-Hodgkin's lymphoma. <i>Cancer</i> , 1988, 62, 2475-2481.	4.0	22
471	Marginal-Zone B-Cell Lymphoma of Extranodal Mucosa-Associated Lymphoid Tissue Type: Molecular Genetics Provides New Insights into Pathogenesis. <i>Advances in Anatomic Pathology</i> , 2001, 8, 313-326.	4.3	22
472	DNA Topoisomerase II \pm in Multiple Myeloma: A Marker of Cell Proliferation and Not Drug Resistance. <i>Modern Pathology</i> , 2001, 14, 886-891.	5.6	22
473	BCL-2 Is Consistently Expressed in Hyperplastic Marginal Zones of the Spleen, Abdominal Lymph Nodes, and Ileal Lymphoid Tissue. <i>American Journal of Surgical Pathology</i> , 2003, 27, 888-894.	3.8	22
474	Usefulness of CD11a and CD18 in Flow Cytometric Immunophenotypic Analysis for Diagnosis of Acute Promyelocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2012, 138, 744-750.	0.7	22
475	The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. <i>Annals of Hematology</i> , 2013, 92, 1335-1343.	1.8	22
476	Epstein-Barr virus \pm positive nodular lymphocyte predominant Hodgkin lymphoma. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 203-209.	1.3	22
477	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015, 28, 1297-1314.	5.6	22
478	Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 514-524.	2.9	22
479	Outcomes in patients with aggressive B \pm cell non \pm Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303.	4.0	22
480	Artificial intelligence strategy integrating morphologic and architectural biomarkers provides robust diagnostic accuracy for disease progression in chronic lymphocytic leukemia. <i>Journal of Pathology</i> , 2022, 256, 4-14.	4.4	22
481	Multiple Myeloma in Association With Sarcoidosis. <i>Archives of Pathology and Laboratory Medicine</i> , 2002, 126, 365-368.	2.5	22
482	Detection of Epstein-Barr Virus in the L & H Cells of Nodular Lymphocyte Predominance Hodgkin \pm Disease: Report of a Case Documented by Immunohistochemical, In Situ Hybridization, and Polymerase Chain Reaction Methods. <i>American Journal of Clinical Pathology</i> , 1997, 108, 687-692.	0.7	21
483	Follicular Lymphoma with Monocytoid B-Cell Proliferation: Molecular Assessment of the Clonal Relationship between the Follicular and Monocytoid B-Cell Components. <i>Laboratory Investigation</i> , 2000, 80, 1593-1599.	3.9	21
484	Signal Transducer and Activator of Transcription-3 Activation Contributes to High Tissue Inhibitor of Metalloproteinase-1 Expression in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 164, 2251-2258.	4.0	21
485	Multiple Myeloma and Immunosecretory Disorders. <i>Advances in Anatomic Pathology</i> , 2008, 15, 196-210.	4.3	21
486	Myelodysplastic Syndrome/Acute Myeloid Leukemia With t(3;21)(q26.2;q22) Is Commonly a Therapy-Related Disease Associated With Poor Outcome. <i>American Journal of Clinical Pathology</i> , 2012, 138, 146-152.	0.7	21

#	ARTICLE	IF	CITATIONS
487	Similarity computation using semantic networks created from web-harvested data. <i>Natural Language Engineering</i> , 2015, 21, 49-79.	3.4	21
488	Law and policy of platform economy in China. <i>Computer Law and Security Review</i> , 2020, 39, 105493.	2.4	21
489	Primary Paratesticular Lymphoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 428-432.	2.5	21
490	Reliability and Significance of Increased Creatine Kinase MB Isoenzyme in the Serum of Uremic Patients. <i>American Journal of Clinical Pathology</i> , 1987, 87, 103-108.	0.7	20
491	Caspase-3 activation in systemic anaplastic large-cell lymphoma. <i>Modern Pathology</i> , 2004, 17, 109-116.	5.6	20
492	Langerhans cell histiocytosis presenting as a thyroid gland mass. <i>Annals of Diagnostic Pathology</i> , 2005, 9, 267-274.	1.3	20
493	Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma. <i>Leukemia Research</i> , 2006, 30, 497-501.	1.1	20
494	8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. <i>Blood</i> , 2010, 116, 5622-5630.	1.4	20
495	A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2011, 6, e28277.	2.5	20
496	Florid reactive lymphoid hyperplasia (lymphoma-like lesion) of the uterine cervix. <i>Annals of Diagnostic Pathology</i> , 2012, 16, 21-28.	1.3	20
497	Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications. <i>Human Pathology</i> , 2013, 44, 2658-2667.	2.3	20
498	Quantitative Assessment of Mutant Allele Burden in Solid Tumors by Semiconductor-Based Next-Generation Sequencing. <i>American Journal of Clinical Pathology</i> , 2014, 141, 559-572.	0.7	20
499	Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: Kinetics of its appearance and potential predictive role in infectious complications. <i>Leukemia Research</i> , 2015, 39, 88-91.	1.1	20
500	Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. <i>Modern Pathology</i> , 2015, 28, 1014-1022.	5.6	20
501	High-grade Transformation of Low-grade B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, e1-e16.	3.8	20
502	Characterization of <i>TP53</i> mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. <i>European Journal of Haematology</i> , 2017, 99, 536-543.	2.2	20
503	Lymphoproliferative disorders with concurrent HHV8 and EBV infection: beyond primary effusion lymphoma and germinotropic lymphoproliferative disorder. <i>Histopathology</i> , 2018, 72, 855-861.	3.0	20
504	Advances in pathological understanding of high-grade B cell lymphomas. <i>Expert Review of Hematology</i> , 2018, 11, 637-648.	2.1	20

#	ARTICLE	IF	CITATIONS
505	Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis. <i>Human Pathology</i> , 2019, 85, 290-298.	2.3	20
506	Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update. <i>Modern Pathology</i> , 2020, 33, 1104-1121.	5.6	20
507	Only <i>SF3B1</i> mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. <i>Cancer</i> , 2021, 127, 3552-3565.	4.0	20
508	Myeloid Sarcoma of Appendix Mimicking Acute Appendicitis. <i>Archives of Pathology and Laboratory Medicine</i> , 2005, 129, 1027-1031.	2.5	20
509	Hodgkin's Disease in Costa Rica: A Report of 40 Cases Analyzed for Epstein-Barr Virus. <i>American Journal of Clinical Pathology</i> , 1998, 109, 618-624.	0.7	19
510	Malignant Fibrous Histiocytoma of the Spermatic Cord: Report of Two Cases and Review of the Literature. <i>Modern Pathology</i> , 2002, 15, 59-65.	5.6	19
511	Side population of a murine mantle cell lymphoma model contains tumour-initiating cells responsible for lymphoma maintenance and dissemination. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 1532-1545.	3.5	19
512	Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine. <i>Cancer</i> , 2009, 115, 4727-4736.	4.0	19
513	Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. <i>Modern Pathology</i> , 2010, 23, 1518-1523.	5.6	19
514	TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation. <i>Modern Pathology</i> , 2013, 26, 195-203.	5.6	19
515	Hydroa vacciniforme and hydroa vacciniforme-like T-cell lymphoma: an uncommon event for transformation. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1102-1111.	1.4	19
516	The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia. <i>Modern Pathology</i> , 2016, 29, 444-451.	5.6	19
517	Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. <i>Cancer</i> , 2018, 124, 3849-3855.	4.0	19
518	Anal adenocarcinoma: Treatment outcomes and trends in a rare disease entity. <i>Cancer Medicine</i> , 2019, 8, 3855-3863.	2.8	19
519	TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. <i>Annals of Diagnostic Pathology</i> , 2019, 41, 38-42.	1.3	19
520	Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. <i>Modern Pathology</i> , 2022, 35, 306-318.	5.6	19
521	CD23 Expression in Mantle Cell Lymphoma: Clinicopathologic Features of 18 Cases. <i>American Journal of Clinical Pathology</i> , 2003, 120, 760-766.	0.7	19
522	Molecular Monitoring of Cerebrospinal Fluid Can Predict Clinical Relapse in Acute Lymphoblastic Leukemia With Eosinophilia. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 601-605.	2.5	19

#	ARTICLE	IF	CITATIONS
523	Genotypic Analysis of Diffuse, Mixed Cell Lymphomas: Comparisons with Morphologic and Immunophenotypic Findings. <i>American Journal of Clinical Pathology</i> , 1991, 95, 547-555.	0.7	18
524	Thrombotic Thrombocytopenic Purpura and HIV Infection. <i>Southern Medical Journal</i> , 1995, 88, 82-86.	0.7	18
525	Endometrial Carcinoma and Non-Hodgkin's Lymphoma Involving the Female Genital Tract: A Report of Three Cases. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 133-138.	1.5	18
526	Progressive Multifocal Leukoencephalopathy with Concurrent Richter's Syndrome. <i>Leukemia and Lymphoma</i> , 2000, 38, 183-190.	1.3	18
527	Combined laser capture microdissection and serial analysis of gene expression from human tissue samples. <i>Modern Pathology</i> , 2005, 18, 577-584.	5.6	18
528	Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. <i>Modern Pathology</i> , 2007, 20, 811-820.	5.6	18
529	Acute Promyelocytic Leukemia at Time of Relapse Commonly Demonstrates Cytogenetic Evidence of Clonal Evolution and Variability in Blast Immunophenotypic Features. <i>American Journal of Clinical Pathology</i> , 2010, 133, 484-490.	0.7	18
530	CD105 (Endoglin) Is Highly Overexpressed in a Subset of Cases of Acute Myeloid Leukemias. <i>American Journal of Clinical Pathology</i> , 2013, 140, 370-378.	0.7	18
531	Evaluation of NF- κ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , 2015, 28, 1202-1213.	5.6	18
532	Follicular lymphoma with hyaline-vascular Castleman-like features: analysis of 6 cases and review of the literature. <i>Human Pathology</i> , 2017, 68, 136-146.	2.3	18
533	Chronic lymphoproliferative disorder of NK cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. <i>European Journal of Haematology</i> , 2018, 100, 444-454.	2.2	18
534	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1066-1071.	4.2	18
535	Reconsideration of the first recognition of breast implant-associated anaplastic large cell lymphoma: A critical review of the literature. <i>Annals of Diagnostic Pathology</i> , 2020, 45, 151474.	1.3	18
536	Anaplastic Large Cell Lymphoma Arising in Bone. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 1339-1343.	2.5	18
537	Quantification of bcl-2/JH Fusion Sequences and a Control Gene by Multiplex Real-Time PCR Coupled with Automated Amplicon Sizing by Capillary Electrophoresis. <i>Journal of Molecular Diagnostics</i> , 2002, 4, 223-229.	2.9	17
538	Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF- κ B activation. <i>Modern Pathology</i> , 2006, 19, 891-898.	5.6	17
539	The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy. <i>International Journal of Cancer</i> , 2011, 128, 2759-2764.	5.3	17
540	Refractory Anemia With Ring Sideroblasts Associated With Marked Thrombocytosis. <i>American Journal of Clinical Pathology</i> , 2011, 135, 398-403.	0.7	17

#	ARTICLE	IF	CITATIONS
541	Chromosome 20q Deletion. American Journal of Clinical Pathology, 2011, 135, 391-397.	0.7	17
542	Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma. Leukemia and Lymphoma, 2012, 53, 990-992.	1.3	17
543	Epstein-Barr virus latent membrane protein-1 up-regulates cytokines and correlates with older age and poorer prognosis in Hodgkin lymphoma. Histopathology, 2017, 70, 442-455.	3.0	17
544	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. American Journal of Hematology, 2018, 93, 1376-1383.	4.2	17
545	Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge. Modern Pathology, 2022, 35, 419-426.	5.6	17
546	Diffuse Aggressive B-Cell Lymphomas of the Gastrointestinal Tract: An Immunophenotypic and Gene Rearrangement Analysis of 22 Cases. American Journal of Clinical Pathology, 1992, 97, 170-178.	0.7	16
547	B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Involving Bone Marrow With an Interfollicular Pattern. American Journal of Clinical Pathology, 2000, 114, 41-46.	0.7	16
548	Uterine Leiomyomas with Eosinophils: A Clinicopathologic Study of 3 Cases. International Journal of Gynecological Pathology, 2001, 20, 239-243.	1.5	16
549	Precursor T-Cell Acute Lymphoblastic Leukemia in Adults. American Journal of Clinical Pathology, 2002, 117, 252-258.	0.7	16
550	Real-Time t(14;18)(q32;q21) PCR Assay Combined with High-Resolution Capillary Electrophoresis: A Novel and Rapid Approach that Allows Accurate Quantitation and Size Determination of bcl-2/JH Fusion Sequences. Modern Pathology, 2002, 15, 448-453.	5.6	16
551	Classical hodgkin lymphoma arising in the rectum. Annals of Diagnostic Pathology, 2005, 9, 38-42.	1.3	16
552	Molecular and Clinicopathologic Characterization of AML With Isolated Trisomy 4. American Journal of Clinical Pathology, 2012, 137, 387-394.	0.7	16
553	CXC Chemokine Receptor 4 Expression, CXC Chemokine Receptor 4 Activation, and Wild-Type Nucleophosmin Are Independently Associated With Unfavorable Prognosis in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 686-692.	0.4	16
554	Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q). Cancer Genetics, 2013, 206, 42-46.	0.4	16
555	Bone marrow involvement by subcutaneous Panniculitis-like T-cell lymphoma: a report of three cases. Modern Pathology, 2014, 27, 800-807.	5.6	16
556	B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 2015, 144, 333-340.	0.7	16
557	Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. Journal of Molecular Diagnostics, 2016, 18, 676-687.	2.9	16
558	NF- κ B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Modern Pathology, 2017, 30, 854-876.	5.6	16

#	ARTICLE	IF	CITATIONS
559	t(3;8)(q26.2;q24) Often Leads to MECOM/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 343-351.	2.9	16
560	KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma. <i>PLoS ONE</i> , 2020, 15, e0238477.	2.5	16
561	Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement. <i>Leukemia Research</i> , 2020, 99, 106460.	1.1	16
562	Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/S�azary syndrome than quantification of <sc>CD26</sc> or <sc>CD7</sc> <sc>CD4</sc>+ T�cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 183-191.	1.6	16
563	Elderly patients� perspectives on treatment, care and rehabilitation after hip fracture: A qualitative systematic review. <i>International Journal of Orthopaedic and Trauma Nursing</i> , 2021, 41, 100811.	1.0	16
564	Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. <i>Oncotarget</i> , 2017, 8, 10845-10857.	2.0	16
565	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. <i>Oncotarget</i> , 2020, 11, 600-618.	2.0	16
566	Anaplastic Lymphoma Kinase (ALK) is not Expressed in Hodgkin's Disease: Results with ALK-11 Antibody in 327 Untreated Patients. <i>Leukemia and Lymphoma</i> , 2001, 42, 969-979.	1.3	15
567	Biological Validation of Differentially Expressed Genes in Chronic Lymphocytic Leukemia Identified by Applying Multiple Statistical Methods to Oligonucleotide Microarrays. <i>Journal of Molecular Diagnostics</i> , 2005, 7, 337-345.	2.9	15
568	Body cavity-based presentation of natural killer cell lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 293-296.	1.3	15
569	Postchemotherapy Histiocyte-Rich Pseudotumor Involving the Spleen. <i>American Journal of Clinical Pathology</i> , 2009, 132, 342-348.	0.7	15
570	Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. <i>Leukemia Research</i> , 2011, 35, 351-357.	1.1	15
571	Phase <sc>II</sc> study of <sc>HCVIDD</sc>/<sc>MA</sc> in patients with newly diagnosed peripheral T�cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 509-516.	2.7	15
572	A Newly Recognized Histologic Pattern of IgG4-related Lymphadenopathy. <i>American Journal of Surgical Pathology</i> , 2018, 42, 977-982.	3.8	15
573	Mantle Cell Lymphoma Involving Skin. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1421-1428.	3.8	15
574	Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. <i>Leukemia and Lymphoma</i> , 2020, 61, 171-175.	1.3	15
575	Immunopathology of Kikuchi�Fujimoto disease: A reappraisal using novel immunohistochemistry markers. <i>Histopathology</i> , 2020, 77, 262-274.	3.0	15
576	Systematic use of fluorescence <i>in situ</i> hybridisation and clinicopathological features in the screening of <i>PDGFRB</i> rearrangements of patients with myeloid/lymphoid neoplasms. <i>Histopathology</i> , 2020, 76, 1042-1054.	3.0	15

#	ARTICLE	IF	CITATIONS
577	<i>MYC</i> rearrangement and MYC/BCL2 double expression but not cell of origin predict prognosis in R-CHOP-treated diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 336-343.	2.2	15
578	B-cell lymphomas associated with breast implants: Report of three cases and review of the literature. <i>Annals of Diagnostic Pathology</i> , 2020, 46, 151512.	1.3	15
579	Massive Mobilization of AML Cells into Circulation by Disruption of Leukemia/Stroma Cell Interactions Using CXCR4 Antagonist AMD3100: First Evidence in Patients and Potential for Abolishing Bone Marrow Microenvironment-Mediated Resistance. <i>Blood</i> , 2006, 108, 568-568.	1.4	15
580	Expression of Tac Antigen by Non-Hodgkin's Lymphomas. <i>American Journal of Clinical Pathology</i> , 1987, 88, 483-485.	0.7	14
581	T-Cell-Rich B-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 1991, 15, 491.	3.8	14
582	Plasma Cell Myeloma Associated With Eosinophilia. <i>American Journal of Clinical Pathology</i> , 1995, 103, 583-587.	0.7	14
583	Lymphoma of the Mucosa-Associated Lymphoid Tissue of the Lung: A Multifocal Case of Common Clonal Origin. <i>American Journal of Clinical Pathology</i> , 1995, 103, 341-345.	0.7	14
584	Gastric Lymphoepithelioma-like Carcinoma and Jejunal B-Cell MALT Lymphoma With Large Cell Transformation: Demonstration of EBV With Identical LMP Gene Deletions in the Carcinoma and Large Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 1996, 105, 560-566.	0.7	14
585	Hodgkin's Disease in Patients Infected with Human Immunodeficiency Virus: Frequency, Presentation and Clinical Outcome. <i>Leukemia and Lymphoma</i> , 2001, 41, 535-544.	1.3	14
586	Quantitative Real-Time Polymerase Chain Reaction for Detection of Circulating Cells with T(14;18) in Volunteer Blood Donors and Patients with Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 1589-1598.	1.3	14
587	Oral-Cutaneous CD4-Positive T-cell Lymphoma: A Study of Two Patients. <i>American Journal of Dermatopathology</i> , 2007, 29, 62-67.	0.6	14
588	Skin involvement in T-cell prolymphocytic leukemia. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 533-534.	1.2	14
589	Detection of Nucleophosmin 1 Mutations by Quantitative Real-Time Polymerase Chain Reaction Versus Capillary Electrophoresis: A Comparative Study. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 994-1000.	2.5	14
590	Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization. <i>Leukemia and Lymphoma</i> , 2014, 55, 2538-2548.	1.3	14
591	Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 882-887.	4.2	14
592	Zircon (Hf, O isotopes) as melt indicator: Melt infiltration and abundant new zircon growth within melt rich layers of granulite-facies lenses versus solid-state recrystallization in hosting amphibolite-facies gneisses (central Erzgebirge, Bohemian Massif). <i>Lithos</i> , 2018, 302-303, 65-85.	1.5	14
593	Bone marrow findings in blast phase of polycythemia vera. <i>Annals of Hematology</i> , 2018, 97, 425-434.	1.8	14
594	Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 492-499.	3.8	14

#	ARTICLE	IF	CITATIONS
595	Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. <i>Cancer</i> , 2018, 124, 2561-2569.	4.0	14
596	A multimodality workup of patients with Hypereosinophilia. <i>American Journal of Hematology</i> , 2018, 93, 1337-1346.	4.2	14
597	The utility of CD83, fascin and CD23 in the differential diagnosis of primary mediastinal large B-cell lymphoma versus classic Hodgkin lymphoma. <i>Annals of Diagnostic Pathology</i> , 2019, 40, 72-76.	1.3	14
598	Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 817-825.	2.3	14
599	High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia. <i>European Journal of Haematology</i> , 2020, 105, 449-459.	2.2	14
600	T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid. <i>Leukemia</i> , 2020, 34, 2509-2512.	7.3	14
601	Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease. <i>Modern Pathology</i> , 2021, 34, 2148-2153.	5.6	14
602	Disseminated ALK-positive histiocytosis with <i>KIF5B-ALK</i> fusion in an adult. <i>Leukemia and Lymphoma</i> , 2021, 62, 1234-1238.	1.3	14
603	Aurora-A kinase nuclear expression in chronic lymphocytic leukemia. <i>Modern Pathology</i> , 2008, 21, 1428-1435.	5.6	13
604	A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Modern Pathology</i> , 2010, 23, 1524-1534.	5.6	13
605	Utility of Quantitative Flow Cytometry Immunophenotypic Analysis of CD5 Expression in Small B-Cell Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 903-909.	2.5	13
606	Modelling rates of gasification of a char particle in chemical looping combustion. <i>Proceedings of the Combustion Institute</i> , 2015, 35, 2785-2792.	4.4	13
607	Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant. <i>American Journal of Clinical Pathology</i> , 2015, 144, 78-86.	0.7	13
608	Preleukemic phase of chronic myelogenous leukemia: morphologic and immunohistochemical characterization of 7 cases. <i>Annals of Diagnostic Pathology</i> , 2016, 21, 53-58.	1.3	13
609	Immunophenotypic Shifts in Primary Cutaneous $\hat{3}$ T-Cell Lymphoma Suggest Antigenic Modulation. <i>American Journal of Surgical Pathology</i> , 2017, 41, 431-445.	3.8	13
610	Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature. <i>Histopathology</i> , 2017, 70, 821-831.	3.0	13
611	Tetraploidy/near-tetraploidy acute myeloid leukemia. <i>Leukemia Research</i> , 2017, 53, 20-27.	1.1	13
612	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. <i>British Journal of Cancer</i> , 2017, 117, 1685-1688.	6.5	13

#	ARTICLE	IF	CITATIONS
613	Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. <i>Cancer Genetics</i> , 2019, 233-234, 21-31.	0.4	13
614	Virtual discrete trial training for teacher trainees. <i>Journal on Multimodal User Interfaces</i> , 2019, 13, 31-40.	2.8	13
615	Blood supply chain: a two-stage approach for tactical and operational planning. <i>OR Spectrum</i> , 2020, 42, 1023-1053.	3.3	13
616	Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2021, 193, 488-496.	2.7	13
617	TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. <i>Modern Pathology</i> , 2004, 17, 96-103.	5.6	13
618	Chronic Myeloid Leukemia Manifested During Megakaryoblastic Crisis. <i>Southern Medical Journal</i> , 1996, 89, 422-427.	0.7	13
619	inv(16)(p13q22) in Chronic Myelogenous Leukemia in Blast Phase. <i>American Journal of Clinical Pathology</i> , 2005, 124, 807-814.	0.7	13
620	<i>MET</i> amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 12959-12970.	2.0	13
621	The Role of the Perifollicular Sinus in Determining the Complex Immunoarchitecture of Angioimmunoblastic T-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1632-1640.	3.8	12
622	B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease. <i>Modern Pathology</i> , 2014, 27, 382-389.	5.6	12
623	Isolated +15 in bone marrow: Disease-associated or a benign finding?. <i>Leukemia Research</i> , 2015, 39, 72-76.	1.1	12
624	PD-L1 and Notch1 expression in KSHV/HHV-8 and EBV associated germinotropic lymphoproliferative disorder: case report and review of the literature. <i>Pathology</i> , 2017, 49, 430-435.	0.7	12
625	Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2018, 24, 2304-2311.	7.1	12
626	Indolent T-lymphoblastic proliferation associated with low grade follicular dendritic cell sarcoma and Castleman disease. <i>Pathology</i> , 2018, 50, 351-352.	0.7	12
627	Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1. <i>Annals of Hematology</i> , 2018, 97, 1775-1783.	1.8	12
628	Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). <i>Cancer Genetics</i> , 2019, 238, 18-22.	0.4	12
629	A longitudinal analysis of urological chronic pelvic pain syndrome flares in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. <i>BJU International</i> , 2019, 124, 522-531.	2.7	12
630	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood Advances</i> , 2019, 3, 1356-1367.	5.3	12

#	ARTICLE	IF	CITATIONS
631	Low-Grade Myelodysplastic Syndromes with Preserved CD34+ B-Cell Precursors (CD34+ Hematogones). Cytometry Part B - Clinical Cytometry, 2020, 98, 36-42.	1.6	12
632	A suggested immunohistochemical algorithm for the classification of T-cell lymphomas involving lymph nodes. Human Pathology, 2020, 102, 104-116.	2.3	12
633	Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Modern Pathology, 2021, 34, 1143-1152.	5.6	12
634	Quantitative PCR Detection of t(14;18) bcl-2/JH Fusion Sequences in Follicular Lymphoma Patients. Journal of Molecular Diagnostics, 2004, 6, 396-400.	2.9	11
635	Somatic Deletions of the PolyA Tract in the 3' Untranslated Region of Epidermal Growth Factor Receptor Are Common in Microsatellite Instability-High Endometrial and Colorectal Carcinomas. Archives of Pathology and Laboratory Medicine, 2012, 136, 510-516.	2.5	11
636	Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy. American Journal of Clinical Pathology, 2016, 145, 271-276.	0.7	11
637	Advances in B-lymphoblastic leukemia: cytogenetic and genomic lesions. Annals of Diagnostic Pathology, 2016, 23, 43-50.	1.3	11
638	Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Human Pathology, 2018, 82, 215-231.	2.3	11
639	Relapsed Acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T-cell therapy: A diagnostic challenge. American Journal of Hematology, 2019, 94, 1049-1051.	4.2	11
640	MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naïve Non-Small-cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e512-e518.	2.6	11
641	Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2831-2838.	1.3	11
642	Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer, 2020, 20, 83.	2.6	11
643	Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution. Cytometry Part B - Clinical Cytometry, 2021, 100, 352-360.	1.6	11
644	Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms. Archives of Pathology and Laboratory Medicine, 2010, 134, e40-e47.	2.5	11
645	Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 2695-2695.	1.4	11
646	Prognostic Implications Of Calbindin-D28k Expression in Lung Cancer: Analysis of 452 Cases. Modern Pathology, 2000, 13, 808-813.	5.6	10
647	Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2005, 42, 87-94.	3.2	10
648	Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma. Blood, 2006, 107, 1240-1241.	1.4	10

#	ARTICLE	IF	CITATIONS
649	Immunohistochemical Analysis of CBFÎ ² -SMMHC Protein Reveals a Unique Nuclear Localization in Acute Myeloid Leukemia With inv(16)(p13q22). American Journal of Surgical Pathology, 2006, 30, 1436-1444.	3.8	10
650	Systemic mastocytosis in association with chronic lymphocytic leukemia: A rare diagnosis. Leukemia Research, 2007, 31, 1755-1758.	1.1	10
651	Clusterin Expression Correlates With Stage and Presence of Large Cells in Mycosis Fungoides. American Journal of Clinical Pathology, 2009, 131, 511-515.	0.7	10
652	Nodular Lymphocyte Predominant Hodgkin Lymphoma With Clusters of LP Cells, Acute Inflammation, and Fibrosis. American Journal of Surgical Pathology, 2009, 33, 1725-1731.	3.8	10
653	Transient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignancies. Leukemia Research, 2011, 35, 1605-1610.	1.1	10
654	Iatrogenic Immunodeficiency-associated Classical Hodgkin Lymphoma. American Journal of Surgical Pathology, 2013, 37, 1895-1897.	3.8	10
655	CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma. American Journal of Clinical Pathology, 2016, 146, 747-752.	0.7	10
656	Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double induction chemotherapy: Analysis from a large, single institution experience. American Journal of Hematology, 2017, 92, 232-237.	4.2	10
657	Dose adjusted EPOCH and mediastinal disease may improve outcomes for patients with gray zone lymphoma. British Journal of Haematology, 2017, 179, 503-506.	2.7	10
658	Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations. British Journal of Haematology, 2018, 181, 305-305.	2.7	10
659	Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. American Journal of Surgical Pathology, 2018, 42, 569-577.	3.8	10
660	Is hyperdiploidy a favorable cytogenetics in adults with B-lymphoblastic leukemia?. Cancer Medicine, 2019, 8, 4093-4099.	2.8	10
661	Social Media for Hematopathologists: Medical Practice Reinvented? #Hemepath. Current Hematologic Malignancy Reports, 2020, 15, 383-390.	2.3	10
662	iAMP21 in acute myeloid leukemia is associated with complex karyotype, TP53 mutation and dismal outcome. Modern Pathology, 2020, 33, 1389-1397.	5.6	10
663	CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. Human Pathology, 2020, 98, 1-9.	2.3	10
664	Higher infiltration of intratumoral CD25+ FOXP3+ lymphocytes correlates with a favorable prognosis in patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2021, 62, 76-85.	1.3	10
665	Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience. Modern Pathology, 2021, 34, 854-861.	5.6	10
666	Epstein-Barr virus latent membrane protein 1 upregulates autophagy and promotes viability in Hodgkin lymphoma: Implications for targeted therapy. Cancer Science, 2021, 112, 1589-1602.	3.9	10

#	ARTICLE	IF	CITATIONS
667	Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).. <i>Blood</i> , 2004, 104, 128-128.	1.4	10
668	Posttransplantation Lymphoproliferative Disorders in Pediatric Patients Undergoing Liver Transplantation. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 337-343.	2.5	10
669	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. <i>Modern Pathology</i> , 2021, , .	5.6	10
670	Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. <i>Modern Pathology</i> , 2022, 35, 1212-1219.	5.6	10
671	Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2022, 14, 3375.	3.8	10
672	Acute Lymphoblastic Leukemia in Elderly Patients. <i>American Journal of Clinical Pathology</i> , 2002, 117, 716-720.	0.7	9
673	c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma. <i>Blood</i> , 2003, 102, 4619-4620.	1.4	9
674	Flow Cytometric Immunophenotypic Analysis of Systemic Mastocytosis Involving Bone Marrow. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1210-1214.	2.5	9
675	Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists. <i>Molecular Cytogenetics</i> , 2016, 9, 62.	1.0	9
676	Clinical significance of acquired loss of the X chromosome in bone marrow. <i>Leukemia Research</i> , 2016, 47, 109-113.	1.1	9
677	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 639-646.	1.2	9
678	Emerging role of zinc finger protein A20 as a suppressor of hepatocellular carcinoma. <i>Journal of Cellular Physiology</i> , 2019, 234, 21479-21484.	4.1	9
679	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427.	2.3	9
680	<i>RAS</i> and <i>TP53</i> can predict survival in adults with Tâ€cell lymphoblastic leukemia treated with hyperâ€CVAD. <i>Cancer Medicine</i> , 2020, 9, 849-858.	2.8	9
681	American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. <i>Annals of Diagnostic Pathology</i> , 2020, 49, 151623.	1.3	9
682	HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients. <i>Aids</i> , 2020, 34, 1735-1743.	2.1	9
683	Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells. <i>Leukemia</i> , 2020, 34, 2460-2472.	7.3	9
684	B-prolymphocytic leukemia: Is it time to retire this entity?. <i>Annals of Diagnostic Pathology</i> , 2021, 54, 151790.	1.3	9

#	ARTICLE	IF	CITATIONS
685	Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups.. Blood, 2006, 108, 2742-2742.	1.4	9
686	Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation. Blood, 2011, 118, 3072-3072.	1.4	9
687	PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas. Biomedicines, 2022, 10, 1587.	3.2	9
688	Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods. Cancers, 2022, 14, 4550.	3.8	9
689	Chromosomal translocations and their role in the pathogenesis of non-Hodgkin's lymphomas. Pathology, 2002, 34, 397-409.	0.7	8
690	Mantle cell lymphoma with a rare involvement of the testicle. Leukemia and Lymphoma, 2007, 48, 1242-1243.	1.3	8
691	Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. Leukemia Research, 2014, 38, 896-900.	1.1	8
692	Clinical Validation of a Multipurpose Assay for Detection and Genotyping of <i>CALR</i> Mutations in Myeloproliferative Neoplasms. American Journal of Clinical Pathology, 2015, 144, 746-755.	0.7	8
693	Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. Cancer Genetics, 2016, 209, 205-214.	0.4	8
694	Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms. Modern Pathology, 2016, 29, 727-734.	5.6	8
695	Additional "structural" chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. Modern Pathology, 2017, 30, 843-853.	5.6	8
696	Synchronous presentation of intra-nodal follicular dendritic cell sarcoma and Castleman disease. American Journal of Hematology, 2017, 92, 478-479.	4.2	8
697	PET-positive lymphadenopathy in CLL "Not always Richter transformation. American Journal of Hematology, 2017, 92, 405-406.	4.2	8
698	Psychometric testing of the Family Carer Diabetes Management Self-Efficacy Scale. Health and Social Care in the Community, 2018, 26, 214-223.	1.6	8
699	Characterization of chronic myelomonocytic leukemia with TP53 mutations. Leukemia Research, 2018, 70, 97-99.	1.1	8
700	Classic Hodgkin lymphoma and Castleman disease: an entity appears to be emerging. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 437-444.	2.9	8
701	The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. Modern Pathology, 2021, 34, 327-335.	5.6	8
702	Syncytial variant of nodular sclerosis Hodgkin lymphoma: an under-emphasized variant. Human Pathology, 2021, 117, 115-125.	2.3	8

#	ARTICLE	IF	CITATIONS
703	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. <i>Modern Pathology</i> , 2021, 34, 2183-2191.	5.6	8
704	The Heidelberg classification of renal cell tumours. <i>Journal of Pathology</i> , 1997, 183, 131.	4.4	8
705	Expression of bcl-3 in Chronic Lymphocytic Leukemia Correlates With Trisomy 12 and Abnormalities of Chromosome 19. <i>American Journal of Clinical Pathology</i> , 2005, 123, 465-471.	0.7	8
706	Immunohistochemical Profile and Fluorescence In Situ Hybridization Analysis of Diffuse Large B-Cell Lymphoma in Northern China. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 759-765.	2.5	8
707	Prevalence and Risk Factors of Dance Injury During COVID-19: A Cross-Sectional Study From University Students in China. <i>Frontiers in Psychology</i> , 2021, 12, 759413.	2.2	8
708	Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 370-376.	2.3	8
709	Chronic Lymphocytic Leukemia Progression Diagnosis with Intrinsic Cellular Patterns via Unsupervised Clustering. <i>Cancers</i> , 2022, 14, 2398.	3.8	8
710	MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome. <i>Cancers</i> , 2022, 14, 2433.	3.8	8
711	Age and Erythrocyte Alloimmunization. <i>Vox Sanguinis</i> , 1986, 51, 73-73.	1.5	7
712	Expression of the activation antigen, 4F2, by non-Hodgkin's lymphomas of B-cell phenotype. <i>Cancer</i> , 1990, 66, 1158-1164.	4.0	7
713	Immunostaining for Rapid Diagnosis of Acute Promyelocytic Leukemia with the Tetramethylrhodamine-5-Isothiocyanate-â€“Conjugated Anti-â€“Promyelocytic Leukemia Monoclonal Antibody PG-M3. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1669-1673.	2.5	7
714	Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells. <i>Modern Pathology</i> , 2015, 28, 1130-1137.	5.6	7
715	Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. <i>Modern Pathology</i> , 2017, 30, 1378-1386.	5.6	7
716	3q26/ EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. <i>Leukemia Research</i> , 2018, 65, 25-28.	1.1	7
717	Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of <i>PDGFRA</i> and <i>ETV6</i> . <i>Oncotarget</i> , 2018, 9, 10987-10994.	2.0	7
718	Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens. <i>Leukemia Research</i> , 2019, 84, 106176.	1.1	7
719	Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2020, 189, 313-317.	2.7	7
720	Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 176-184.	1.3	7

#	ARTICLE	IF	CITATIONS
721	Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. <i>Modern Pathology</i> , 2021, 34, 300-313.	5.6	7
722	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1361-1369.	1.3	7
723	t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?. <i>Annals of Hematology</i> , 2020, 99, 487-500.	1.8	7
724	Pleural Posttransplantation Lymphoproliferative Disorder Following Liver Transplantation. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 419-423.	2.5	7
725	Artificial intelligence-assisted mapping of proliferation centers allows the distinction of accelerated phase from large cell transformation in chronic lymphocytic leukemia. <i>Modern Pathology</i> , 2022, 35, 1121-1125.	5.6	7
726	del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2009, 192, 18-23.	0.9	6
727	Usefulness of Flow Cytometric Immunophenotyping for Bone Marrow Staging in Patients With Mantle Cell Lymphoma After Therapy. <i>American Journal of Clinical Pathology</i> , 2012, 137, 634-640.	0.7	6
728	Capsular Contracture and Axillary Lymphadenopathy in Breast Implant-associated ALK-negative Anaplastic Large Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1736-1738.	3.8	6
729	t(15;17)(q24.1;q21.2)/PML-RARA in blast phase of chronic myelogenous leukemia: a rare form of clonal evolution. <i>Journal of Hematopathology</i> , 2013, 6, 187-193.	0.5	6
730	Phenotypic evolution in a case of peripheral T-cell lymphoma suggests the presence of tumor heterogeneity. <i>Journal of Cutaneous Pathology</i> , 2013, 40, 573-579.	1.4	6
731	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1225-1227.	2.5	6
732	Starry Sky Pattern in Hematopoietic Neoplasms: A Review of Pathophysiology and Differential Diagnosis. <i>Advances in Anatomic Pathology</i> , 2016, 23, 343-355.	4.3	6
733	Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma in a patient treated with azathioprine for ulcerative colitis. <i>Pathology</i> , 2016, 48, 513-515.	0.7	6
734	Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. <i>American Journal of Clinical Pathology</i> , 2016, 145, 418-427.	0.7	6
735	Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. <i>Annals of Hematology</i> , 2017, 96, 501-504.	1.8	6
736	Clinical significance of isolated del(7p) in myeloid neoplasms. <i>Leukemia Research</i> , 2017, 55, 18-22.	1.1	6
737	Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells. <i>Pathology</i> , 2017, 49, 544-547.	0.7	6
738	Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement. <i>Aesthetic Surgery Journal</i> , 2018, 38, .	2.3	6

#	ARTICLE	IF	CITATIONS
739	Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for <i>RHOA</i> G17V mutated subtype. <i>Leukemia and Lymphoma</i> , 2020, 61, 1108-1118.	1.3	6
740	Myeloid neoplasm with eosinophilia and BCR-JAK2/t(9;22)(p24;q11.2) morphologically mimicking chronic myeloid leukemia. <i>Annals of Diagnostic Pathology</i> , 2020, 44, 151405.	1.3	6
741	Dehydroabietylamine-based thiazolidin-4-ones and 2-thioxoimidazolidin-4-ones as novel tyrosyl-DNA phosphodiesterase 1 inhibitors. <i>Molecular Diversity</i> , 2021, 25, 2389-2397.	4.0	6
742	MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma. <i>Human Pathology</i> , 2021, 108, 22-31.	2.3	6
743	Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1405-1412.	2.5	6
744	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. <i>Blood Cancer Journal</i> , 2021, 11, 52.	6.3	6
745	The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1 α and VEGF and Synergizes with Everolimus In Hodgkin Lymphoma Cell Lines. <i>Blood</i> , 2010, 116, 2851-2851.	1.4	6
746	Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 3964-3964.	1.4	6
747	Pathologic Quiz Case: A Unilateral Renal Mass in an Elderly Woman. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 919-920.	2.5	6
748	Peripheral T-Cell Lymphoma With a "Follicular" Pattern and the Perifollicular Sinus Phenotype. <i>American Journal of Clinical Pathology</i> , 2005, 123, 448-455.	0.7	6
749	The White Blood Cell Differential: Evaluation of Rapid Impression Scanning Versus the Routine Manual Count. <i>American Journal of Clinical Pathology</i> , 1987, 87, 628-632.	0.7	5
750	Transthyretin (Prealbumin) Immunoreactivity in Renal Cell Carcinoma and Other Neoplasms. <i>International Journal of Surgical Pathology</i> , 1996, 4, 1-7.	0.8	5
751	Deletion 15q as the sole abnormality in acute myeloid leukemia: report of three cases and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2009, 188, 118-123.	0.9	5
752	<i>TP53</i> mutation is rare in primary myelofibrosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 1552-1552.	1.3	5
753	Cytarabine, Ki67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. <i>Cancer</i> , 2013, 119, 3318-3325.	4.0	5
754	On the significance of negative-pressure wound therapy with instillation in dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 786-795.	0.7	5
755	Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 445-447.	1.3	5
756	Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2017, 92, E168-E171.	4.2	5

#	ARTICLE	IF	CITATIONS
757	3q26.2/EV11 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Modern Pathology</i> , 2017, 30, 940-951.	5.6	5
758	Higher body mass index is associated with better survival in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2018, 71, 63-66.	1.1	5
759	Development and Application of Duplex Sequencing Strategy for Cell-Free DNA-Based Longitudinal Monitoring of Stage IV Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 994-1009.	2.9	5
760	Utility of Cyclin D1 in the Diagnostic Workup of Hematopoietic Neoplasms: What Can Cyclin D1 Do for Us?. <i>Advances in Anatomic Pathology</i> , 2019, 26, 281-291.	4.3	5
761	Clinical characteristics and outcomes of duodenal-type follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3266-3268.	1.3	5
762	CD123 Expression in Philadelphia Chromosome-like B Acute Lymphoblastic Leukemia/Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e317-e320.	0.4	5
763	CD56 TdT blastic natural killer cell tumor of the skin. <i>Cancer</i> , 2002, 94, 2401-2408.	4.0	5
764	Postchemotherapy Histiocyte-rich Pseudotumor Mimicking Residual Lymphoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 160-168.	3.8	5
765	Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. <i>Blood</i> , 2018, 132, 4151-4151.	1.4	5
766	Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome. <i>Blood</i> , 2019, 134, 3016-3016.	1.4	5
767	Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 3718-3718.	1.4	5
768	Kikuchi disease with an exuberant proliferation of large T cells: a study of 25 cases that can mimic T cell lymphoma. <i>Histopathology</i> , 2023, 82, 340-353.	3.0	5
769	T-prolymphocytic leukemia: TCL1 or MTCP1 rearrangement is not mandatory to establish diagnosis. <i>Leukemia</i> , 2023, 37, 1919-1921.	7.3	5
770	CD20+ nodal marginal zone B-cell lymphoma with CD20 recurrence as an intracranial dural-based mass. <i>Leukemia and Lymphoma</i> , 2006, 47, 2253-2256.	1.3	4
771	An Attractive Therapeutic Target, mTOR Pathway, in ALK+ Anaplastic Large Cell Lymphoma. <i>Advances in Anatomic Pathology</i> , 2008, 15, 105-112.	4.3	4
772	Flow cytometry immunophenotypic analysis of philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features. <i>Cytometry Part B - Clinical Cytometry</i> , 2015, 88, 236-243.	1.6	4
773	Characterization of TP53 mutations in clonal cytopenia of undetermined significance. <i>American Journal of Hematology</i> , 2017, 92, E175-E177.	4.2	4
774	Dermal myeloid sarcoma as an initial presentation of acute myeloid leukemia. <i>Blood</i> , 2017, 129, 1056-1056.	1.4	4

#	ARTICLE	IF	CITATIONS
775	Refractory hairy cell leukemiaâ€variant. American Journal of Hematology, 2017, 92, 1398-1399.	4.2	4
776	Delta-like homolog1/GATA binding protein 2 axis mediates leptin inhibition of PPAR β 2 expression in hepatic stellate cells in vitro. Life Sciences, 2018, 192, 183-189.	4.3	4
777	Three new disease-progression modes in NSCLC patients after EGFR-TKI treatment by next-generation sequencing analysis. Lung Cancer, 2018, 125, 43-50.	2.0	4
778	CT and 18F- FDG-PET-CT Findings in Secondary Adrenal Lymphoma with Pathologic Correlation. Academic Radiology, 2019, 26, e108-e114.	2.4	4
779	Philadelphia chromosomeâ€negative acute leukemia in patients with chronic myeloid leukemia. American Journal of Hematology, 2019, 94, E256-E259.	4.2	4
780	TdT-positive high grade B-cell lymphoma transformed from grade 3B follicular lymphoma in an HIV-positive patient. Pathology, 2019, 51, 764-768.	0.7	4
781	Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors. Cancer Genetics, 2020, 241, 57-60.	0.4	4
782	Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma. Annals of Diagnostic Pathology, 2020, 49, 151636.	1.3	4
783	Incidental identification of inv(16)(p13.1q22)/CBFBâ€MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. Cold Spring Harbor Molecular Case Studies, 2021, 7, a006084.	1.3	4
784	Future of Education or Present Reality?. Archives of Pathology and Laboratory Medicine, 2021, 145, 1350-1354.	2.5	4
785	Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. Leukemia and Lymphoma, 2021, 62, 3296-3299.	1.3	4
786	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clinical Cancer Research, 2021, 27, 5847-5856.	7.1	4
787	Inhibition of AKT/mTOR Signaling Induces Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma.. Blood, 2005, 106, 2415-2415.	1.4	4
788	Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma.. Blood, 2009, 114, 3744-3744.	1.4	4
789	Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma. Modern Pathology, 2022, 35, 412-418.	5.6	4
790	Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases. Human Pathology, 2021, 118, 60-68.	2.3	4
791	CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. Cancers, 2021, 13, 5354.	3.8	4
792	Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas. Cancers, 2022, 14, 1186.	3.8	4

#	ARTICLE	IF	CITATIONS
793	3q26.2/MECOM Rearrangements by Pericentric Inv(3): Diagnostic Challenges and Clinicopathologic Features. <i>Cancers</i> , 2023, 15, 458.	3.8	4
794	The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation. <i>Cancers</i> , 2023, 15, 198.	3.8	4
795	High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. <i>Blood Advances</i> , 2023, 7, 6381-6394.	5.3	4
796	Donor-derived isolated del(20q) after hematopoietic stem cell transplantation: report of two cases and review of the literature. <i>Journal of Hematopathology</i> , 2013, 6, 25-32.	0.5	3
797	Acquired B cell immunophenotype of follicular dendritic cells in a B cell-depleted lymph node after treatment with rituximab. <i>Annals of Hematology</i> , 2014, 93, 1947-1948.	1.8	3
798	β -Glutamyl Transferase Testing, Change of Its Designation on the Laboratory Request Form, and Resulting Ratio of Inappropriate to Appropriate Use. <i>Laboratory Medicine</i> , 2015, 46, 265-270.	1.0	3
799	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1228-1230.	2.5	3
800	Feminization of the fat distribution pattern of children and adolescents in a recent German population. <i>American Journal of Human Biology</i> , 2017, 29, e23017.	1.6	3
801	Update on Lymphoma classification: The 2016 revised World Health Organization Classification of Hematopoietic and Lymphoid Neoplasms. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e57.	0.9	3
802	Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies. <i>Data in Brief</i> , 2019, 24, 104025.	1.1	3
803	Medium-Range Narratives as a Complementary Tool to Principle-Based Prioritization in Sweden: Test Case of ADHD. <i>Journal of Bioethical Inquiry</i> , 2019, 16, 113-125.	1.6	3
804	Villous lymphocytes in splenic large B-cell lymphoma with diffuse red pulp infiltration. <i>International Journal of Hematology</i> , 2019, 109, 133-134.	1.5	3
805	Lymphoma 2020: an update on recent advances in pathobiology and application to clinical practice. <i>Pathology</i> , 2020, 52, 1-5.	0.7	3
806	Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <i>Leukemia and Lymphoma</i> , 2020, 61, 963-966.	1.3	3
807	Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. <i>Leukemia and Lymphoma</i> , 2020, 61, 3243-3246.	1.3	3
808	LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2020, 99, 2343-2349.	1.8	3
809	Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis. <i>Modern Pathology</i> , 2020, 33, 2035-2045.	5.6	3
810	Epstein-Barr virus specific cytotoxic T lymphocytes for the treatment of severe Epstein-Barr virus mucocutaneous ulcer. <i>British Journal of Haematology</i> , 2020, 189, e33-e36.	2.7	3

#	ARTICLE	IF	CITATIONS
811	Formal and informal support and counselling for embryo donation and receipt: An Australian qualitative study. <i>Health and Social Care in the Community</i> , 2020, 28, 950-957.	1.6	3
812	Langerhans cell sarcoma involving skin and showing epidermotropism: A comprehensive review. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 547-557.	1.4	3
813	Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome. <i>Experimental and Molecular Pathology</i> , 2021, 118, 104572.	2.2	3
814	From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia. <i>Annals of Diagnostic Pathology</i> , 2021, 53, 151767.	1.3	3
815	MDMX/MDM4 is highly expressed and contributes to cell growth and survival in anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1563-1573.	1.3	3
816	Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. <i>Blood</i> , 2018, 132, 451-451.	1.4	3
817	ALK+ large B-cell lymphoma with aberrant expression of CD3. <i>Blood</i> , 2020, 136, 3086-3086.	1.4	3
818	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2011, 118, 949-949.	1.4	3
819	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 641-641.	1.4	3
820	RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1730-1730.	1.4	3
821	In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. <i>Blood</i> , 2015, 126, 3192-3192.	1.4	3
822	Indolent Neuroendocrine Tumor Involving the Bone Marrow. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 488-491.	2.5	3
823	cDNA Microarray Analysis of Genes Associated with NPM-ALK Overexpression in Anaplastic Large Cell Lymphomas.. <i>Blood</i> , 2004, 104, 2269-2269.	1.4	3
824	Clinicopathological features of syncytial variant nodular sclerosis Hodgkin lymphoma. <i>Human Pathology</i> , 2022, 119, 105-113.	2.3	3
825	The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis. <i>Cancers</i> , 2021, 13, 6316.	3.8	3
826	Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. <i>Pathology</i> , 2023, 55, 514-524.	0.7	3
827	Introduction to the Fifth Edition of the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. <i>Modern Pathology</i> , 2023, 36, 100330.	5.6	3
828	Effects of Six Different Tissue Fixatives on DNA Quality as Determined by Polymerase Chain Reaction Amplification of Genes Ranging from 100 to 574 Base Pairs. <i>Journal of Histotechnology</i> , 2003, 26, 111-115.	0.7	2

#	ARTICLE	IF	CITATIONS
829	Current Problems With Staging Lymphomas Involving the Ovary. American Journal of Surgical Pathology, 2006, 30, 1202-1203.	3.8	2
830	Type B Core Binding Factor β /Smooth Muscle Myosin Heavy Chain Fusion Transcript in Myeloid Blast Phase of Chronic Myeloid Leukemia: Correlation with Nuclear and Cytoplasmic Localization of the Fusion Protein. Clinical Leukemia, 2008, 2, 257-260.	0.3	2
831	V(D)J recombination and staggered DNA breaks: guilty again. Blood, 2010, 115, 2121-2122.	1.4	2
832	Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. Journal of Medical Case Reports, 2016, 10, 209.	0.8	2
833	Commentary: Comparison of historical medical spending patterns among the BRICS and G7. Frontiers in Pharmacology, 2016, 7, 213.	3.6	2
834	Constitutional pericentric inversion of chromosome 9 has no impact on survival in chronic myelogenous leukemia. Annals of Hematology, 2016, 95, 657-659.	1.8	2
835	Fifteen-Year Journey to High Reliability in Pathology and Laboratory Medicine. American Journal of Medical Quality, 2018, 33, 530-539.	0.6	2
836	Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. OncoTargets and Therapy, 2018, Volume 11, 8937-8942.	2.1	2
837	Kikuchi disease: an unusual case with features suggesting an infectious aetiology. Pathology, 2018, 50, 694-697.	0.7	2
838	Gaucher disease type 1 first recognized in an elderly patient with thrombocytopenia and lung adenocarcinoma. Clinical Case Reports (discontinued), 2019, 7, 1804-1805.	0.5	2
839	Epstein - Barr virus infection in de novo diffuse large B-cell lymphoma in Jordan and Turkey. Annals of Diagnostic Pathology, 2019, 43, 151406.	1.3	2
840	Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leukemia Research, 2019, 86, 106227.	1.1	2
841	Phenytoin-associated necrotising lymphadenitis mimicking Kikuchi disease. Pathology, 2019, 51, 650-653.	0.7	2
842	Molecular analysis of melanocytic naevus arising from ovarian mature teratoma. Pathology, 2019, 51, 663-665.	0.7	2
843	Scale-aware camera localization in 3D LiDAR maps with a monocular visual odometry. Computer Animation and Virtual Worlds, 2019, 30, e1879.	1.2	2
844	The emergence of a <i>JAK2</i> V617F-mutated clone in myelodysplastic syndrome is associated with disease progression and features of myelofibrosis. British Journal of Haematology, 2019, 186, 396-396.	2.7	2
845	Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes. Experimental and Molecular Pathology, 2019, 108, 131-136.	2.2	2
846	Biclonal presentation of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia. Pathology, 2019, 51, 340-343.	0.7	2

#	ARTICLE	IF	CITATIONS
847	Ring sideroblasts in chronic phase of polycythemia vera identifies a subset of patients with an increased risk of progression to blast phase. <i>Annals of Diagnostic Pathology</i> , 2019, 40, 45-48.	1.3	2
848	Hydroa Vacciniformeâ€“Like Lymphoproliferative Disorder With Progression to EBV+ Cytotoxic Peripheral T-Cell Lymphoma. <i>American Journal of Dermatopathology</i> , 2020, 42, 714-716.	0.6	2
849	CD45â€“negative follicular lymphoma: A rare diagnostic pitfall of a common entity. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 406-408.	1.6	2
850	Leukemic phase of Richter transformation: A mimic of acute myeloid leukemia that responded to Ibrutinib monotherapy. <i>American Journal of Hematology</i> , 2020, 95, 1221-1223.	4.2	2
851	From the archives of MD Anderson Cancer Center: A case of concurrent follicular lymphoma and Langerhans cell sarcoma with a review of the literature. <i>Annals of Diagnostic Pathology</i> , 2021, 52, 151720.	1.3	2
852	Hematogones with light chain restriction: A potential diagnostic pitfall when using flow cytometry analysis to assess bone marrow specimens. <i>Leukemia Research</i> , 2021, 111, 106704.	1.1	2
853	Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2021, 108, 106616.	1.1	2
854	Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation â€“ First case series from a single institution. <i>Leukemia Research</i> , 2021, 111, 106685.	1.1	2
855	Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. <i>Blood</i> , 2018, 132, 1599-1599.	1.4	2
856	Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).. <i>Blood</i> , 2006, 108, 2749-2749.	1.4	2
857	Integrated Genome Sequencing Reveals Frequent Loss of Function Alterations of ARID1A and Other Epigenetic Modifiers in Sezary Syndrome. <i>Blood</i> , 2014, 124, 706-706.	1.4	2
858	Benefit of Consolidative Autologous Stem Cell Transplantation in First Complete Remission for Patients with Double Hit Lymphoma Appears Dependent on Induction Regimen Intensity. <i>Blood</i> , 2016, 128, 3455-3455.	1.4	2
859	The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4153-4153.	1.4	2
860	Networking Modules of Canonical and Alternative NFkB Signaling in Growth and Survival Regulations of Large B Cell Lymphomas. <i>Blood</i> , 2008, 112, 3776-3776.	1.4	2
861	Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms of the Ocular Adnexa. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 336-340.	2.5	2
862	Neurofibroma and Cellular Neurofibroma with Atypia: A report of 14 tumors. <i>American Journal of Surgical Pathology</i> , 1999, 23, 1156.	3.8	2
863	Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML. <i>Blood</i> , 2021, 138, 607-607.	1.4	2
864	3â€“CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant. <i>Annals of Hematology</i> , 2022, 101, 847-854.	1.8	2

#	ARTICLE	IF	CITATIONS
865	Nodular Lymphocyte-predominant Hodgkin Lymphoma With Nodular Sclerosis. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1291-1297.	3.8	2
866	Blastoid B-Cell Neoplasms: Diagnostic Challenges and Solutions. <i>Cancers</i> , 2023, 15, 848.	3.8	2
867	Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. <i>Blood Advances</i> , 2023, 7, 7393-7401.	5.3	2
868	Myeloid neoplasm with $\leq 10\%$ blasts and $t(3;5)(q25.1;q34)/NPM::MLF1$: A classification dilemma. <i>American Journal of Hematology</i> , 0, , .	4.2	2
869	Expression of Helix-Loop-Helix Proteins in Classical Hodgkin Lymphoma: A Possible Explanation for a Characteristic Immunophenotype. <i>Advances in Anatomic Pathology</i> , 2008, 15, 97-104.	4.3	1
870	Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-CHOP: A Report From an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S382.	0.4	1
871	7. Additional structural chromosomal abnormalities have a negative prognostic effect in patients with $inv(16)/t(16;16)$ acute myeloid leukemia (AML). <i>Cancer Genetics</i> , 2019, 233-234, S3-S4.	0.4	1
872	Unicentric Castleman disease, hyaline vascular variant, stromal rich, with increased plasma cells and a high level of serum IL-6: Raising the diagnostic and therapeutic issues. <i>Annals of Diagnostic Pathology</i> , 2019, 43, 151398.	1.3	1
873	MALT lymphoma with IgM paraprotein and bone marrow involvement mimicking Waldenström macroglobulinaemia. <i>Pathology</i> , 2019, 51, 549-553.	0.7	1
874	Unusual case of human herpesvirus 8-positive large B-cell lymphoma associated with Castleman disease. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 587-588.	0.5	1
875	Tumour-stage mycosis fungoides initially misdiagnosed as Langerhans cell histiocytosis. <i>Pathology</i> , 2020, 52, 593-596.	0.7	1
876	From the archives of MD Anderson Cancer Center: BCR-ABL1-like B acute lymphoblastic leukemia with IGH/EPOR fusion. <i>Annals of Diagnostic Pathology</i> , 2020, 46, 151514.	1.3	1
877	Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia. <i>British Journal of Haematology</i> , 2020, 189, e207-e211.	2.7	1
878	From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later. <i>Annals of Diagnostic Pathology</i> , 2021, 50, 151649.	1.3	1
879	Localized non-Hodgkin lymphoma involving the thyroid gland. <i>Cancer</i> , 2001, 91, 629-635.	4.0	1
880	Posttransplant Lymphoproliferative Disorder Involving the Gastrointestinal Tract. <i>Journal of Digestive Endoscopy</i> , 2020, 11, 293-294.	0.2	1
881	Addition of Rituximab to Mobilization and Conditioning Overcomes the Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) Score in Patients with Relapsed FL Undergoing Autologous Stem Cell Transplantation (AUTO). <i>Blood</i> , 2008, 112, 1140-1140.	1.4	1
882	Early Mixed T-Lymphocyte and Myeloid Chimerism Is Predictive of Disease Recurrence Following Allogeneic Stem Cell Transplantation for AML/MDS. <i>Blood</i> , 2012, 120, 3075-3075.	1.4	1

#	ARTICLE	IF	CITATIONS
883	Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 544-544.	1.4	1
884	MYC Copy Number Aberrancies Predict a Worse Prognosis in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 154-154.	1.4	1
885	Routine Clinical Testing for Actionable Mutations in CLL Using Endc11 Assay V1: The Initial MD Anderson Experience. <i>Blood</i> , 2016, 128, 3196-3196.	1.4	1
886	Cytogenetic Abnormalities May Predict Transformation to Acute Myeloid Leukemia in Polycythemia Vera Patients. <i>Blood</i> , 2016, 128, 4258-4258.	1.4	1
887	Inhibition of AKT/mTOR Signaling Pathway Induces Cell Cycle Arrest and Apoptosis in Acute Myelogenous Leukemia.. <i>Blood</i> , 2005, 106, 2355-2355.	1.4	1
888	Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).. <i>Blood</i> , 2009, 114, 2310-2310.	1.4	1
889	STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 365-365.	1.4	1
890	Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL). <i>Blood</i> , 2014, 124, 2563-2563.	1.4	1
891	Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2014, 124, 143-143.	1.4	1
892	Novel Gene Translocations Involving TYK2 in Cutaneous CD30-Positive Lymphoproliferative Disorders. <i>Blood</i> , 2014, 124, 3032-3032.	1.4	1
893	Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2015, 126, 2011-2011.	1.4	1
894	Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1719-1719.	1.4	1
895	MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients. <i>Blood</i> , 2019, 134, 1560-1560.	1.4	1
896	A Tissue Section-Based Near-Infrared Spectroscopical Analysis of Salivary Gland Tumors. <i>Cancers</i> , 2021, 13, 5356.	3.8	1
897	High-Throughput Characterization of Cytogenomic Heterogeneity of MDS Using High-Resolution Optical Genome Mapping. <i>Blood</i> , 2021, 138, 105-105.	1.4	1
898	Artificial Intelligence-Assisted Mapping of Proliferation Centers in Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Identifies Patterns That Reliably Distinguish Accelerated Phase and Large Cell Transformation. <i>Blood</i> , 2021, 138, 1558-1558.	1.4	1
899	Unexpected myeloid sarcoma of the tonsil in a patient without a history of hematological neoplasm. <i>Blood</i> , 2022, 139, 148-148.	1.4	1
900	Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2022, 116, 106827.	1.1	1

#	ARTICLE	IF	CITATIONS
901	From the archives of MD Anderson Cancer Center: Intravascular large B-cell lymphoma with numerous circulating lymphoma cells. <i>Annals of Diagnostic Pathology</i> , 2022, 58, 151934.	1.3	1
902	Primary mediastinal germ cell tumor and clonally related and unique hematologic neoplasms with i(12p) and TP53 mutation: A report of two cases. <i>Annals of Diagnostic Pathology</i> , 2022, 59, 151951.	1.3	1
903	Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. <i>Modern Pathology</i> , 0, , .	5.6	1
904	Recurrent Somatic Copy Number Alterations and Their Association with Oncogene Expression Levels in High-Grade Ovarian Serous Carcinoma. <i>Life</i> , 2023, 13, 2192.	2.5	1
905	Optical Genome Mapping Helps to Identify BCR::JAK2 Rearrangement Arising from Cryptic Complex Chromosomal Aberrations: A Case Report and Literature Review. <i>Genes</i> , 2023, 14, 2188.	2.4	1
906	Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy. <i>Pathology</i> , 2024, 56, 367-373.	0.7	1
907	Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. <i>Blood Cancer Journal</i> , 2024, 14, .	6.3	1
908	PRIMARY NODULAR LYMPHOMA OF THE LUNG Immunoperoxidase and Ultrastructural Studies. <i>Pathology International</i> , 1982, 32, 835-842.	1.3	0
909	Progress in T-Cell and NK-Cell Malignancies. <i>American Journal of Clinical Pathology</i> , 2007, 127, 494-495.	0.7	0
910	Unusual expression of CD94 on CD8+ TCR- $\alpha\beta$ T cells in infectious mononucleosis. <i>Annals of Diagnostic Pathology</i> , 2007, 11, 55-60.	1.3	0
911	4.27 Genomic Variability Predicts Time-to-Treatment in Previously Untreated CLL Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S237-S238.	0.4	0
912	Transcription and Translation are Primary Targets of Pim Kinase Inhibitor SGI-1776 in Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S383.	0.4	0
913	Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large B-cell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S146-S147.	0.4	0
914	TET2 Mutations, Myelodysplastic Features, and a Distinct Immunoprofile Characterize Blastic Plasmacytoid Dendritic Cell Neoplasm in the Bone Marrow. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S128.	0.4	0
915	Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S228.	0.4	0
916	Myeloproliferative Neoplasms with Calreticulin Mutations Exhibit Distinctive Morphologic Features. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S57.	0.4	0
917	MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S223.	0.4	0
918	Introduction to the 2013 Workshop of the Society for Hematopathology/European Association for Haematopathology. <i>American Journal of Clinical Pathology</i> , 2015, 144, 4-5.	0.7	0

#	ARTICLE	IF	CITATIONS
919	Acute Myeloid Leukemia with t(v;5q33-34) Does Not Always have Myelodysplastic Features but is Associated with Poor Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S187-S188.	0.4	0
920	Clinical and prognostic significance of 3q26 rearrangements and other chromosome 3 abnormalities in chronic myelogenous leukemia in era of tyrosine kinase inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S32-S33.	0.4	0
921	A rare histologic variant of a common lymphoma. <i>Blood</i> , 2016, 128, 3012-3012.	1.4	0
922	Implementation of Genotyping Cell Free Nucleic Acid in Plasma Using Next Generation Sequencing Platforms in a Clinical Laboratory. <i>Cancer Genetics</i> , 2016, 209, 291-292.	0.4	0
923	Validation of a Multiplex Capillary Electrophoresis-Based Assay for Simultaneous Detection of the Common and Uncommon BCR-ABL1 Transcripts. <i>Cancer Genetics</i> , 2016, 209, 289-290.	0.4	0
924	Isolated Sex Chromosome Loss after Allogeneic Stem Cell Transplant in Patients With Hematological Malignancies. <i>Cancer Genetics</i> , 2016, 209, 241.	0.4	0
925	Reply to Lambros et al. <i>Modern Pathology</i> , 2018, 31, 541-542.	5.6	0
926	First Reported Case of Composite Breast Implant-associated Anaplastic Large Cell Lymphoma and Marginal Zone Lymphoma. <i>American Journal of Clinical Pathology</i> , 2018, 150, S100-S101.	0.7	0
927	Granular B-acute lymphoblastic leukemia: Ultrastructural characterization of cytoplasmic granules. <i>Leukemia Research</i> , 2018, 73, 105-107.	1.1	0
928	Oral iron as treatment for iron deficiency: Should it always be the first choice?. <i>Medicina Clínica (English Edition)</i> , 2018, 151, e27-e28.	0.2	0
929	Myelodysplastic Syndromes with EZH2 Mutations Frequently Show Multilineage Dysplasia, Chromosome 7 Alterations and Concomitant Mutations in ASXL1, RUNX1 and TET2. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S260.	0.4	0
930	Reactive lymphadenopathy with concurrent idiopathic plasma cell variant Castleman disease, amyloid deposition and non-caseating granulomas. <i>Pathology</i> , 2019, 51, 762-764.	0.7	0
931	Levels of CD8+ tumor infiltrating lymphocytes correlate with disease burden in bone marrow of therapy Naïve multiple myeloma patients. <i>Annals of Diagnostic Pathology</i> , 2019, 40, 174-175.	1.3	0
932	Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes. <i>Cancers</i> , 2020, 12, 1903.	3.8	0
933	Biopreservation and Biobanking's Mid-Year Update. <i>Biopreservation and Biobanking</i> , 2020, 18, 257-257.	1.1	0
934	MPN-402: Delayed Resolution of Bone Marrow Morphological Changes of Myelofibrosis Following Successful Stem Cell Transplant and Molecular Clearance of Disease: A Cautionary Tale. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S340-S341.	0.4	0
935	Reply to "PD-L1 expression in anaplastic large cell lymphoma". <i>Modern Pathology</i> , 2020, 33, 1234-1235.	5.6	0
936	Clinicopathologic Features of Myelodysplastic Syndromes Involving Lymph Nodes. <i>American Journal of Surgical Pathology</i> , 2021, Publish Ahead of Print, 930-938.	3.8	0

#	ARTICLE	IF	CITATIONS
937	Follicular dendritic cell sarcoma in the differential diagnosis of GATA3 positive tumors: A case report. <i>Human Pathology: Case Reports</i> , 2021, 23, 200473.	0.2	0
938	Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis â€” Chronic Myelomonocytic Leukemia and Beyond. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 286-303.	2.3	0
939	TCL1 Expression in B-Cell Tumors Is Dynamically Regulated by Maturation Stage, Proliferation, and the Follicular Microenvironment.. <i>Blood</i> , 2004, 104, 4333-4333.	1.4	0
940	Heat Shock Protein 90 (HSP90) Inhibition by the Small Molecule 17-AAG Induces Cell Cycle Arrest and Apoptosis in Anaplastic Large Cell Lymphoma (ALCL) Irrespective of ALK Expression: Role of Akt, ERK and ALK Kinases in the Molecular Mechanisms of 17-AAG Anti-Tumor Activity.. <i>Blood</i> , 2005, 106, 2811-2811.	1.4	0
941	A Biologically Distinctive Subgroup of Acute Myelogenous Leukemia with Characteristic Nuclear Morphology and a High Frequency of FLT3 Mutation.. <i>Blood</i> , 2005, 106, 4522-4522.	1.4	0
942	Heat Shock Protein 90 (HSP90) Is Overexpressed in Primary and Cultured Hodgkin Lymphoma (HL) Cells: Role of Therapeutic Targeting Using the Small Molecule Inhibitor 17-AAG.. <i>Blood</i> , 2005, 106, 2422-2422.	1.4	0
943	Differential Expression of the Homeobox Gene MIXL1 in Non Hodgkin (NHL) and Hodgkin Lymphomas (HL).. <i>Blood</i> , 2005, 106, 3014-3014.	1.4	0
944	Activation of mTOR Signaling Pathway Contributes to Tumoral Cell Survival in ALK-Positive Anaplastic Large Cell Lymphoma.. <i>Blood</i> , 2005, 106, 2419-2419.	1.4	0
945	cJun Is Phosphorylated at Ser73 and Contributes to Cell Cycle Progression in Anaplastic Large Cell Lymphoma.. <i>Blood</i> , 2005, 106, 2620-2620.	1.4	0
946	Nutlin-3A, an MDM2 Antagonist, Induces p53-Dependent Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma (HL).. <i>Blood</i> , 2006, 108, 2506-2506.	1.4	0
947	Overexpression of CXCR4 in Acute Myeloid Leukemia Predicts Adverse Overall and Progression-Free Survival Independently of FLT3 Gene Mutation.. <i>Blood</i> , 2006, 108, 1890-1890.	1.4	0
948	NPM-ALK Promotes Cell Cycle Progression through Activation of JNK and c-Jun in Anaplastic Large Cell Lymphoma.. <i>Blood</i> , 2006, 108, 2057-2057.	1.4	0
949	Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia: The M. D. Anderson Cancer Center Experience. <i>Blood</i> , 2008, 112, 5068-5068.	1.4	0
950	Simultaneous Targeting of SHH/ p53 Pathways in Large B Cell Lymphomas.. <i>Blood</i> , 2009, 114, 1730-1730.	1.4	0
951	12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years.. <i>Blood</i> , 2011, 118, 4138-4138.	1.4	0
952	Aberrant Expression of Golgin-84 in Non-Hodgkin Lymphomas and Plasma Cell Myeloma. <i>Blood</i> , 2011, 118, 4633-4633.	1.4	0
953	Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Blood</i> , 2012, 120, 3554-3554.	1.4	0
954	Dasatinib Therapy Affects Bone Homeostasis in Patients with Chronic Myelogenous Leukemia in Chronic Phase Independently of Molecular Response. <i>Blood</i> , 2012, 120, 1682-1682.	1.4	0

#	ARTICLE	IF	CITATIONS
955	Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT). Blood, 2013, 122, 3350-3350.	1.4	0
956	MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 363-363.	1.4	0
957	NF- κ B Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2014, 124, 1620-1620.	1.4	0
958	Comparison of Risk Models for Patients with Lower Risk Myelodysplastic Syndromes. Blood, 2014, 124, 1919-1919.	1.4	0
959	Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes. Blood, 2014, 124, 4658-4658.	1.4	0
960	Clinical and Biological Features of Primary Testicular B-Cell Lymphoma - a Single-Institution Study of 89 Cases. Blood, 2014, 124, 3036-3036.	1.4	0
961	MYC Expression Is Prognostic in Therapy Related Acute Myeloid Leukemia (AML) and AML with Myelodysplastic Syndrome (MDS)-Related Changes. Blood, 2014, 124, 5334-5334.	1.4	0
962	MYC/BCL2 Double Hit Lymphoma: What Really Matters. Blood, 2015, 126, 3909-3909.	1.4	0
963	Validation of the 2016 Revision to the World Health Organization (WHO) Classification of Myelodysplastic Syndromes with Diploid Karyotype. Blood, 2016, 128, 4319-4319.	1.4	0
964	CD5 Negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Cases. Blood, 2016, 128, 2964-2964.	1.4	0
965	Clinical Implementation of a Testing Algorithm for the Diagnosis of Ph-like B-Cell Acute Lymphoblastic Leukemia. Blood, 2016, 128, 2915-2915.	1.4	0
966	Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients. Blood, 2018, 132, 1600-1600.	1.4	0
967	Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience. Blood, 2018, 132, 4651-4651.	1.4	0
968	RAS and TP53, Not NOTCH1, Can Predict Survival in Adults with Acute T-Cell Lymphoblastic Leukemia Treated with Hypercvad. Blood, 2018, 132, 4085-4085.	1.4	0
969	Features of an Unusual AML with t(4;12)/Pdgra-ETV6 As the Sole Cytogenetic Abnormality Associated with Myelodysplastic Changes: A Case Report and Literature Review. Blood, 2019, 134, 5162-5162.	1.4	0
970	High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes. Blood, 2019, 134, 5438-5438.	1.4	0
971	NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint Regulation. Blood, 2019, 134, 2796-2796.	1.4	0
972	Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL). Blood, 2019, 134, 322-322.	1.4	0

#	ARTICLE	IF	CITATIONS
973	Gene Expression Profiling Using Nanostring [®] Reveals Differences According to Location, Histology and MIPI Score in Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 5218-5218.	1.4	0
974	Using Antigen Expression of Leukemic Cells for a Fast Screening of Acute Promyelocytic Leukemia by Flow Cytometry. <i>Diagnostics</i> , 2021, 11, 1988.	2.7	0
975	HHV8-Associated Lymphoproliferative Disorders. , 2020, , 439-446.		0
976	Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. <i>Blood</i> , 2021, 138, 4536-4536.	1.4	0
977	Machine Learning Pipeline with Feature Engineering Provides Robust Diagnostic Predictions in Chronic Lymphocytic Leukemia, Accelerated and Transformed Phases. <i>Blood</i> , 2021, 138, 3738-3738.	1.4	0
978	Outcome of Patients with T-Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. <i>Blood</i> , 2021, 138, 1448-1448.	1.4	0
979	Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. <i>Pathology</i> , 2022, , .	0.7	0
980	PPP1R7 Is a Novel Translocation Partner of CBFβ via t(2;16)(q37;q22) in Acute Myeloid Leukemia. <i>Genes</i> , 2022, 13, 1367.	2.4	0
981	Intracranial inflammation-rich germinoma mimicking haematological neoplasms: a diagnostic pitfall. <i>Pathology</i> , 2022, , .	0.7	0
982	Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. <i>Biology</i> , 2023, 12, 13.	2.9	0
983	TdT-positive high-grade B-cell lymphoma with BCOR and IDH1 mutations. <i>Pathology</i> , 2023, , .	0.7	0
984	Origin of the terms "water pot"™ and "starry sky"™ in Burkitt lymphoma. <i>Pathology</i> , 2023, , .	0.7	0
985	Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells. <i>Cancers</i> , 2023, 15, 5690.	3.8	0
986	Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissues: B-cell Neoplasms. <i>Modern Pathology</i> , 2024, 37, 100441.	5.6	0
987	Low-grade histiocytic sarcoma with aggressive clinical behaviour: an unusual case with novel genetic mutations identified by whole genome sequencing. <i>Pathology</i> , 2024, , .	0.7	0
988	High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series. <i>Blood Advances</i> , 0, , .	5.3	0